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ABSTRACT
Hantaviruses are members of the virus family Bunyaviridae that cause two
potentially lie- threatening diseases in humans: hemorrhagic fever with renal syndrome
(HFRS) and hantavirus pulmonary syndrome (BPS). HFRS is caused by Old World
hantaviruses that are endemic in many Asian and European countries. Infections with
Old World hantaviruses can range in severity from asymptomatic to moderate or severe
depending primarily on the infecting serotype of virus. BPS is caused by New World
hantaviruses in North and South America. New World hantaviruses are rarely
asymptomatic and are severe in the majority of cases. These syndromes are distinct from
one another in the primary target organ of virus infection (kidney vs. lung), but have
important clinical features in common, including fever, thrombocytopenia, and a
capilary leak syndrome. These common clinical manifestations suggest that the
underlying mechanisms of disease may be similar in the two syndromes.
The precise mechanisms of pathogenesis of HFS and BPS are poorly
characterized, but may be mediated in par by immunopathology. Hantaviruses are able
to establish infections in many human cell types, including primary human endothelial
cells , without having any cytopathic effect on these cells. Human infections with
hantavirus result in a robust activation of the humoral and cellular immune response , and
we hypothesize that these immune responses contribute to the pathology of disease.
Evidence for the activation of T lymphocytes , and their potential involvement in
immunopathology, includes increases in the number of circulating, activated CD8+ T
cells during HFRS , the presence of lymphocytic infiltrates (predominantly CD8+ T cells)
in kidney biopsies from patients with acute HFS , and associations between certain HLA
haplotype and disease severity following hantavirus infection. This thesis is the first
examination of human T lymphocyte responses that are generated during HFRS.
Initially, we studied memory T cell responses in scientists who were sub-clinically
infected with Hantaan virus (HTNV), the prototype hantavirus. We later investigated
memory T cell responses in healthy Finnish adults who had HFS caused by Puumala
virus (PUUV), a hantavirus endemic primarly in Scandinavia.
At the onset of these studies , there was no available information on human T
lymphocyte responses to Old World hantaviruses. Virus-specific CD8+ and CD4+ human
T cell lines had been isolated from patients with acute BPS caused by Sin Nombre virus
(SNV) infection. In that study, conducted in our laboratory, several human T cell
epitopes on the nucleocapsid (N) protein and G2 envelope glycoprotein of SNV were
identified and characterized. We decided to perform similar analyses on PBMC from
donors who had been infected with HTNV and PUU , in order to determne the
specificity and diversity of the T cell response to Old World hantaviruses.
The initial study of three donors who had sub-clinical infections with HTNV
demonstrated that virus-specific T cell responses could be detected in all the donors
following in vitro stimulation of PBMC with inactivated virus. In two of the donors , the
virus-specific cytolytic T cells (CTL) recognized the HTNV N protein, and in the third
donor the virus-specific CTLs recognized the HTNV Gl glycoprotein. Isolation and
characterization of virus-specific T cells from two donors resulted in the identification of
two CDS+ T cell epitopes on the HTNV N protein , which were restricted by either HLA
Al or B51. These CTL lines included both HTNV-specific (HLA B51-restricted) and
serotype-cross reactive (HLA Al restricted) lines. In one subject, these virus-specific T
cell responses were detectable in IF-y ELlS POT assays following peptide stimulation
and in bulk cultures after short-term stimulation with inactivated HTNV. These results
indicated that the CDS+ CTL responses of humans after sub-clinical infection with HTNV
were readily detectable and were directed against a limited number of viral proteins and
epitopes. In addition , sub-clinical infection resulted in the generation of both virus-
specific and cross-reactive CTL responses.
We reasoned that hantavirus infections that lead to clinical ilness may result in
the generation of more robust and/or diverse virus-specific T cell responses than in sub-
clinical infections. To address this question, we studied the memory CD8+ T cell
responses in a group of healthy adults from Finland who had HFS caused by PUU
infection between the years 1984 and 1995. We detected virus-specific CTL in the bulk
cultures of seven of eleven immune individuals tested following stimulation with
infectious virus. The PUUV proteins N, Gland G2 were recognized by CTLs in six
five , and two donors respectively. Extensive cloning of T cells from two donors resulted
in the isolation of sixty-three virus-specific CTL lines , the majority of which (61/63)
were specific for the PUU N protein. Six novel CD8+ CTL epitopes and one CD4+
CTL epitope were identified on the N protein , all of which clustered in the center of the
protein between amino acids 173 and 251. The CTL lines specific for these epitopes
were restricted by a varety of HLA alleles including A2 , A28, B7 and B8, and were
primarily serotype specific when tested against target cells expressing HTNV or SNV N
protein. IFN-y ELISPOT analysis using the defined epitopes to stimulated PBMC
revealed high frequencies of circulating N-specific CDS+ T cells in eight of thirteen
individuals tested. Finally, T cell receptor (TCR) VB analysis of CTL clones specific for
one epitope (N204 demonstrated that cells in this population expressed up to five
different VB chains. These results demonstrated that the PUUV N protein may be the
dominant target of the CTL response , that the N-specific CDS+ CTL responses are
diverse , heterogeneous , and primarly serotype specific , and that virus-specific memory
CDS+ T cells can persist at high levels for up to 15 years after the primary infection.
In order to understand the pathology of HFS and BPS , we must be able to assess
the contribution of various factors that could potentially contribute to disease. The virus
burden in the infected individual is likely to be an important factor in the severity of the
resulting disease. Quantitative RT-PCR analysis of plasma samples from acute BPS
patients demonstrated that a higher virus burden (as reflected by viral RNA copy number)
is associated with more severe BPS. In order to perform similar analyses in patients with
HFRS caused by PUUV , we established a quantitative RT-PCR assay for the detection of
PUU S segment RNA in patient plasma. The design and optimization of the PUU-
specific RT-PCR is described in this report. This assay wil allow us to measure the virus
. burden in patients and compare these data with levels of T cell activation and with
parameters of disease severity. In this way, we hope to gain an understanding of the
kinetics and magnitude of both the virus burden and virus-specific T cell response during
the acute ilness.
V1l
This thesis provides the first description of human virus-specific T cell responses
to HTNV and PUUV. These data shed light on the nature of the CDS+ T cell responses
that are generated following natural infections with PUU and sub-clinical infections
with HTNY. The studies of memory CDS+ T cell responses to PUUV , and the
development of a PUUV-specific quantitative RT-PCR assay, establish the framework
for future studies of the immunopathology of acute HFS. Quantitative analysis of both
virus burden and T cell responses during acute ilness wil provide insight into their
relative contributions to the pathology of disease.
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CHAPTER I
INTRODUCTION
The genus Hantavirus of the virus family Bunyaviridae is comprised of more than
twenty viruses , approximately half of which are known to cause human disease (1 , 2).
Hantaviruses are rodent-borne viruses that are transmitted to humans by inhalation of
aerosolized virus paricles that are shed in rodent excreta. This characteristic renders
hantaviruses distinct from the other four genera of the famly Bunyaviridae which are
transmitted via arhropod vectors (3). Hantavirus infection in humans can result in the
development of two distinct and potentially life-threatening diseases: hemorrhagic fever with
renal syndrome (HFRS) and hantavirus pulmonary syndrome (BPS) (2 4). Some examples of
different hantaviruses , their rodent hosts and resulting diseases are shown in Table I-
HFRS is caused by Old World hantaviruses endemic in many Asian and European
countries including China, Japan , Korea, Russia, Finland, Sweden , Hungary, France
Belgium, Germany, Slovakia and Slovenia. Approximately 100 000-200 000 clinical cases of
HFRS are reported annually, more than half of which occur in China (1 , 5). Human disease
resulting from Old World hantavirus infections can range from a subclinical or mild ilness to
a moderate or severe syndrome, depending primarily on the infecting strain of virus. The
most severe cases of HFRS are characterized by fever, hemorrhage and renal failure and are
fatal in 5-15% of cases (4 , 5). Hantaan virus (HTNV), the prototype hantavirus , was first
isolated in 1978. HTNV , which is cared by the striped field mouse (Apodemus agrarius), 
endemic primarly in Asia and causes a severe form of HFS (6). Other hantaviruses that
cause HFS include Dobrava virus (DOBV), cared by the yellow-necked field mouse
(Apodemus flavicolls) in the Balkans; Seoul virus (SEOV), cared by the gray rat (Rattus
norvegicus) worldwide; and Puumala virus (PUU), carred by the bank vole (Clethrionomys
glareolus) in Scandinavia, Western Europe and the Balkans. DOBV and SEOV are
associated with moderate to severe forms of HFRS, while PUUV causes a milder disease (also
called nephropathica epidemic a or NE).
Recent outbreaks of ilness in the Southwestern United States and South America have
resulted in the isolation of a newly recognized group of hantaviruses (e.g. Sin Nombre (SNV)
and Andes (ANDV) viruses) that cause the fatal pulmonary disease BPS (7-9). BPS causes
severe disease in most cases and has a case fatality rate of 30-50%.
HFS and BPS are distinct in the predominant target organ of virus infection (kidney
vs. lung) but have important clinical features in common including fever, thrombocytopenia
and a capilary leak syndrome (2 , 10). The common clinical manifestations suggest that the
underlying mechanism of disease may be similar in the two syndromes.
Table 1- 1. Members of the Hantavirus enus.
Virus Host Distribution Disease
Hantaan Apodemus agrarius China, Russia HFS (severe)
(HTNV) Korea
Seoul Rattus norvegicus Worldwide HFS (moderate)
(SEOV) Rattus rattus
Dobrava/Belgrade Apodemus Balkans HFS (severe)
(DOBV) flavicolls
Puumala Clethrionomys Europe , Russia HFS (mild)(PUU) glareolus Scandinavia
Prospect Hill Microtus North America none documented
(PHV) pennsylvanicus
Tula Microtus arvalis Europe none documented
(TUL V)
Sin Nombre Peromyscus North America BPS
(SNV) maniculatus Mexico
New York Peromyscus North America BPS
(NYV) leucopus
Bayou Oryzomys palustris North America BPS (renal)
(BA YV)
Black Creek Canal Sigmodon hispidus North America BPS (renal) 
(BCCV)
Andes Oligoryzomys South America BPS (renal)
(ANDV) longicaudatus
A. HANT A VIRUS VIROLOGY
Like all viruses in the genus Bunyavirus hantaviruses are enveloped viruses with a
diameter of 90- 110 nm and a segmented , single-stranded RNA genome. The virus genome
consists of three strands of negative-sense RNA designated S (small; 1600-2100 nt), M
(medium; -3700 nt) and L (large; -6500 nt) (11). The hantavirus RNA segments are flanked
by short, complementary regions of 9- 11 nucleotides which may hybridize to form panhandle
structures, similar to those seen in electron micrographs of other members of the bunyavirus
genus (11). Each RNA segment contains a single long open reading frame and encodes a
single protein product (3 , 12).
The S segment encodes the viral nucleocapsid (N) protein , a 45K protein that
associates with the viral RNA in the mature virion (13), and is thought to playa role in
replication and encapsidation of the viral RNA (14 , 15). Cross-linking and electrophoresis
mobility shift studies utilizing deletion RNA derivatives and synthetic oligoribonucleotides
have demonstrated that the N protein binds to the 5' untranslated region of the S segment
(16). The N proteins from the different hantaviruses share an overall amino acid homology of
approximately 50% , although specific regions of the protein are more or less highly conserved
(amino acids 340-433 are 85% homologous; amino acids 240-310 are 11 % homologous). N
proteins of closely related viruses such as HTNV and SEOV, or SNV and PUU , are more
highly conserved, sharing approximately 80-85% and 70-71 % identity at the amno acid level
respectively (12 , 17).
The M RNA segment encodes the precursor to the envelope glycoproteins , which is
co-translationally cleaved into the mature Gl and G2 envelope glycoproteins (18, 19). 
and G2 are type I glycoproteins that dimerize in the ER and are subsequently transported to
the Golgi where virus assembly and budding occur (3). The glycoproteins are thought to bind
If '4--
the virus receptors on target cells , which have recently been identified as members of the 
integrin family of proteins (20 , 21). Comparsons of the nucleotide sequences of the M
segment from varous hantaviruses shows that the M and S segments share a comparable
degree of homology. This suggests that the Sand M segments have evolved at approximately
the same rate (12). This is in contrast to other RNA viruses , such as influenza, in which the
external proteins mutate at a significantly faster rate than the internal proteins (22). The
amino acid sequence identity of the Gland G2 proteins ranges from 50-S0% between
different hantaviruses. The position of several conserved cysteine residues within the protein
sequences suggests that the overall structure of the glycoproteins is essentially the same
among all hantaviruses (19).
The L segment encodes the viral RNA-dependent RNA polymerase (23). The L
protein is believed to carry out both transcription and replication of the viral genome , as well
as the transcription of complementary and messenger RNAs. The L segment has a slightly
higher level of nucleotide sequence homology between the hantaviruses than the S or M
segments , which is likely to reflect a more stringent requirement for conservation of structure
and/or function for the replicative enzyme than for the nucleocapsid or the envelope
glycoproteins (12).
Hantaviruses are cared in nature by rodents belonging to the munnae , sigmodontinae
and arvicolinae subfamilies of the rodent family Muridae , 24). Each hantavirus is cared
by a distinct rodent species and phylogenetic analysis of viral nucleotide sequences suggests
that hantaviruses have co-evolved with their rodent hosts for thousands of years. Hence
hantaviruses that are carred by the same subfamly of rodent (e.g. HTNV , DOBV and SEOV)
are more genetically and antigenically similar to one another than those carred by different
rodent subfamilies. A phylogenetic tree of the different hantaviruses (based on the nucleotide
sequences of the S segment) is shown in Figure I-
'
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B. HANTA VIRUS ECOLOGY AND EPIDEMIOLOGY
1. Virus transmission and tissue localization in natural rodent hosts.
Hantaviruses are maintained in nature via cyclical transmission between rodents.
Infection of the natural rodent hosts appears to be lifelong and asymptomatic (1, 25).
Infection between mice is thought to occur in an age-dependent, horizontal fashion and this
has been demonstrated in both wild (25 26) and experimental settings (27-29). Transmission
may occur by bites inflcted during aggressive encounters or via inhalation of contamnated
aerosols from urine, feces and saliva (25 , 30). Observations of PUUV infection among wild
bank voles also suggest that transmission among rodents may depend on the sexual maturity
of the rodents , particularly for males (25). In this study, seroconversion occurred more
frequently during the reproductive season of the vole and in sexually mature males. This may
reflect increased aggressive behavior, communal nesting habits and increased mobility of the
rodents , all of which generally occur at the onset of sexual maturity.
In some species of rodents that carry New World hantaviruses , such as Sigmodon
hispidus (31), Peromyscus manniculatus (32) and Reithrodontomys megalotis (2), male mice
are more commonly infected than females. However, in other species , like C. glareolus sex-
related differences in seroprevalence are uncommon. Young rodents possess protective
maternal antibodies against hantavirus , which disappear by 35-45 days of age , after which the
rodents become susceptible to hantavirus infection (25, 27, 33).
Infection results in extensive dissemination of virus in the rodent. There is a transient
viremia during which time the animals are capable of transmitting virus in a horizontal
fashion (25 , 30 , 31 , 34 , 35). Evidence from natural and experimentally infected animals
indicates that virus replication and shedding reach a peak during the first month of infection
and decrease thereafter (25, 31), although the duration and intensity of infectious virus
shedding varies with the host species and infecting virus. A study of wild-caught bank voles
demonstrated that PUUV -specific antibodies , virus antigen , infectious virus and the ability to
transmit virus to cage-mates lasted for at least 15 months after infection (25). In that study,
antibodies persisted throughout this time period, while the intensity of virus reproduction , the
frequency of horizontal transmission and the accumulation of PUU antigen decreased over
time (25). Viral antigen and infectious virus can be detected in varous organs of the infected
rodent including hear, lung, liver, spleen , kidney and brown fat as well as in urine , feces and
saliva (30 , 31 , 34 , 36). Following experimental infection of P. maniculatus the natural
reservoir for SNV , the highest titers of viral RNA and levels of viral antigen were detected in
the heart, lung and brown fat (34). Studies examning the specific types of cells infected by
hantaviruses in mice are sparse. However, the aforementioned study of SNV infection in 
maniculatus found that the cells infected with the virus had the characteristic morphology of
endothelial cells (34). Following natural infections with PUU in bank voles, strong
cytoplasmic staining of macrophage-like cells in the lungs was observed (25). These data
suggest that endothelial cells and macrophages are likely targets of hantavirus infection in
rodent hosts , and studies of experimental infection in rodents support this finding (29 , 37).
2. Immune responses in natural rodent hosts.
Infected rodents mount both humoral and cellular immune responses to hantaviruses.
Most of the evidence for this is derived from studies in which wild-caught rodents are
experimentally infected with their native hantavirus species (30, 34). Experimental infections
of wild bank voles (c. glareolus) infected with PUU showed that virus-specific antibody
responses appeared 18 days after intra-muscular (Lm.) inoculation and were maximal 4-
weeks post-inoculation (29). Antibody levels persisted at moderate levels for the duration of
that study (270 days). Similar kinetics of antibody generation were observed following
experimental infection of S. hispidus with Black Creek Canal virus (BCCV) and infection of
P. maniculatus with SNV (31 , 34). As the rodents generate an immune response, the amount
of viral antigen decreases , but virus is not cleared and can persist in the lung and other tissues
for at least one year after infection (25 , 30 , 35). To date , no studies of T cell responses to
hantavirus infection have been performed in the natural host species, but some groups have
observed that infected organs often contain monocytic infiltrates , which may include activated
T lymphocytes (35, 38).
No signs of clinical ilness were apparent in the rodent hosts in any of these studies
(25 34). Most studies also revealed a lack of gross histopathological changes in infected
organs of mice (29 , 30 , 39). However, studies of Peromyscus maniculatus and P. leucopus
which cary SVV and New York virus (NYV) respectively, have shown evidence of septal
edema in lung tissue and mononuclear cell infiltrates in the liver (35 , 38). The authors of
these two studies suggested that such changes in tissue morphology are similar to those
associated with SNV infections in humans. However, the general consensus is that hantavirus
infection in the natural rodent hosts is completely asymptomatic (27 , 40).
3. Transmission of hantavirus to humans.
Hantavirus infection of humans is considered to be an accidental, "spil-over
infection that occurs via inhalation of aerosolized virus paricles shed in rodent excreta.
Outbreaks of hantavirus disease in humans have been associated with increases in rodent
populations , which fluctuate with season , food supply and weather patterns (40 41). Human
infections are also associated with activities that increase contact between rodents and humans
, 42). Spring and summer outbreaks of HFS in agricultural settings in Asia and Europe
have been associated with contact between humans and field rodents related to the planting
and haresting of crops (24). In Scandinavian countries, the incidence of HFS peaks in the
fall and winter months , which correlates with the movement of rodents into man-made
structures such as houses and barns (43). Occupational risk of hantavirus infection is high
among animal trappers , forestry workers , farmers and military personnel due to an increased
likelihood of contact with rodents (44).
Outbreaks of human hantavirus infection have also occurred in laboratories in which
scientists were working with hantaviruses or handling infected laboratory rats. Laboratory
infections have been reported in Japan , Korea, Belgium , England and France (4 , 45-4S). 
one laboratory outbreak in Korea, the infections occurred only during the months of
November through April. The authors of that report suggested that factors such as limited air
circulation and lower humidity in the animal rooms during the winter months may have
increased the probability of virus aerosolization and transmission (45).
Human-to-human transmission is not thought to occur with most hantaviruses (42).
However, there have been two reports of human-to-human transmission of ANDV in
Argentina (42 49), in which healthcare workers and friends of BPS patients were infected
with genetically identical viruses. Many of the individuals who contracted BPS following
patient contact had never been to the endemic region before and had no evident contact with
rodents (49), suggesting that transmission occurred through contact with infected humans.
4. Seroprevalence in humans and rodents.
Antibodies to hantaviruses can be detected in humans and rodents throughout the
world with seroprevalence rates varying widely, depending on the geographic region and
virus species in question. Seroepidemiology studies in the most endemic regions of Norway
reported that up to 30% of individuals over 60 years of age were hantavirus seropositive (50
51). A similar study of I SOO individuals in an endemic area in rural China reported that 12%
of the population was hantavirus seropositive. Seropositive individuals in that study ranged in
age from 2-79 years , and antibody prevalence increased with age (52). In the Philippines , the
overall seroprevalence rate was approximately 6% , with little varation between rural , urban
and urban poor areas (53). In other non-endemic areas , the reported seroprevalence rates
were much lower than in endemic areas , often 1 % or less (54). Comparisons of
seroprevalence rates and hospitalized cases of HFRS suggest that there are many mild or
asymptomatic hantavirus infections in Europe and Asia. The ratio of virus infections to
hospitalized ilness ranges from approximately 15: 1 for PUUV infections to 5: 1 for HTNV
infections (52 , 55).
Serological evidence of past infection with Sin Nombre-like hantaviruses was
demonstrated in a study of approximately 200 Indians living in South America. In that study,
17% of Indians living in Western Paraguay and over 40% of Indians living in northern
Argentina were antibody-positive , with seroprevalence increasing with age in both
populations (56). Studies of these populations are of paricular interest since clinically
apparent disease appears to be rare in these regions. This observation might suggest that a
less pathogenic hantavirus circulates in this area, or that native American populations are
genetically resistant to disease. In another study, 23 BPS cases were reported in the Filadelfia
area of Western Paraguay with a low case fatality rate of 17% (57). Interestingly, the
majority of clinical cases in this region occurred among the Mennonites , who are not
indigenous to the area, whereas very few cases were reported among the native Indians.
Again , this suggests that the indigenous populations may be more resistant to severe ilness
caused by hantavirus infection. Alternatively, the authors of that study proposed that the
native Indian population may experience greater exposure to the virus due to poor living
conditions and/or that the Mennonites may be more likely to report ilnesses. This low
mortality rate is in stark contrast to Sin Nombre virus infections in the southwestern U.S.
which have an overall case fatality rate of approximately 50%.
Rodents throughout the world have been shown to harbor infections with varous
hantaviruses. Serological analysis of rodents trapped in endemic areas of China and
Scandinavia showed that 30-40% of rodent species known to harbor hantaviruses had
measurable virus-specific antibodies (52 , 55 , 58). In Taiwan, where Seoul virus appears to be
the only hantavirus in circulation , seroprevalence rates ranged from 5% in rural regions to
20% in international seaports , where the R. rattus and R. norvegicus carer species are most
prevalent (59). A study conducted in Slovenia reported a 20% seropositivity rate among
Apodemus species trapped at five study sites over a six year period (60). Sequence analysis of
M segment PCR products amplified from the kidney tissues of seropositive rodents in that
study revealed that two distinct lineages of DOBV co-circulate in the area.
Several studies have reported seasonal and yearly varations in seroprevalence rates.
A study of wild-caught red bank voles (c. glareolus) in Belgium reported a high
seroprevalence (47.7%) in the spring of 1999 , a year associated with a marked increase in
rodent density (26). This increase in rodent seroprevalence was also associated with
increased disease in humans (61). However, in earlier years much lower seroprevalence rates
( -
6%) were observed.
Recent serologic studies have been performed on rodents in the Americas. Serologic
surveys of rodents in California and Nevada demonstrated that approximately 12% of 
maniculatus tested had antibodies to SNV (62, 63). A large study examining hantavirus
seroprevalence among rodents in U.S. National Parks demonstrated that rodents throughout
the U.S. are antibody-positive for SNV , with the overall prevalence rate ranging from 2%
(Peromyscus leucopus) to 33% (Reithrodontomys megalotis) in different rodent species (32).
Interestingly, the seroprevalence among Peromyscus species (P. maniculatus and P. leucopus)
was highest in the northeast, where few cases of BPS have been identified. These data
demonstrate the potential for human infection with hantaviruses throughout the United States.
C. CLINICAL DISEASE AND DIAGNOSIS IN HUMANS
As noted earlier, hantaviruses can cause two distinct and severe syndromes in humans:
hemorrhagic fever with renal syndrome (HFS) and hantavirus pulmonary syndrome (BPS).
The outcome of infection depends primarly on the infecting strain of hantavirus. In general
hantaviruses that are endemic in Asia and Europe primarily target the kidney and cause
HFS , while hantaviruses endemic in North and South America target the lung and cause
BPS. The genetic basis for the distinct tropism between the different hantaviruses has not
been established. In recent years, detailed clinical analysis of patients with acute hantaviral
infections has revealed that many of the 'classical' symptoms of HFS are seen in some BPS
cases , and vice versa (1).
1. HFRS
HFS can appear as a mild, moderate or severe disease , depending primarly on the
infecting strain of virus. HTNV and DOBV are known to cause the most severe forms of
HFS , while PUU causes a less severe form of disease , often referred to as nephropathia
epidemica (NE). Mortality rates range from less than 1 % for HFS caused by PUU to 5-
15% for HFS caused by HTNV (24 , 64). The genetic differences among the viruses that
contribute to the differences in pathogenicity have yet to be elucidated.
It has been estimated that approximately 30-40% of individuals infected with HTNV
wil experience a mild clinical course of disease , 50-60% wil exhibit a moderate course and
20-30% wil experience severe forms of HFS (4 , 58). Severe HFS typically occurs in four
overlapping phases: febrile , hypotensive (shock), oliguric and diuretic (2 , 65 , 66). However
it is not uncommon , especially in mild and moderately severe cases , for some of the
characteristic phases to be inapparent and the boundares between phases blurred.
Disease onset follows an incubation period of 2-3 weeks and is characterized by the
rapid appearance of non-specific , flu-like symptoms including high fever, chils , myalgia
abdominal and lumbar pain , and malaise (58 , 67). During the febrile phase , characteristic
hemorrhagic manifestations appear including conjunctival injection , face and neck flushing,
petechiae of the skin and soft palate , and retroperitoneal edema (4 , 58 , 66 , 67). These
symptoms indicate a generalized alteration in the function of the small blood vessels (68).
These bleeding manifestations are commonly observed in severe HFS, but are rare in milder
infections such as those caused by PUUV (67). Most of the clinical features of HFS that
develop during and after the febrile phase are thought to be a result of general capilary
dysfunction (68 , 69).
Defervescence marks the beginning of the hypotensive (shock) phase, which can last
from a few hours to several days. The degree of hypotension can range from mild decreases
in blood pressure to profound shock and circulatory collapse , which is attributable to vascular
leak (66). Common symptoms observed during this phase of HFS include tachycardia
restlessness , nausea and vomiting. Typical laboratory abnormalities include proteinuria
thrombocytopenia and hemoconcentration (64). Thrombocytopenia and hemoconcentration
are hallmarks of capilary leakage , which are characteristic of HFS (and BPS) (70).
Capilary hemorrhages appear to be most prominent during this phase of the syndrome and
predominantly affect the renal medulla, right atrium and gastrointestinal submucosa (66). In
addition to the cardiac hemorrhage that is frequently observed during HFS , there is also a
characteristic mononuclear cell infitration of the edematous layer immediumtely beneath the
endocardial endometrium (66). Hemorrhages of the renal medulla rarely result from the
rupture or loss of continuity of vessels , but are instead thought to be the result of vascular
engorgement and diapedesis of red blood cells (66). Approximately one-third of deaths occur
during this phase due to irreversible circulatory shock that results from massive fluid loss.
Indeed, most fatal cases show evidence of moderate to severe retroperioneal edema upon
autopsy (64 , 66 , 69 , 71).
During the oliguric phase , blood pressure begins to normalize , and some patients
experience transient hypertension due to constriction of capilaries and reabsorption of fluid
(66, 68). Hemoconcentration and decreased blood volume are generally reversed very rapidly
upon recovery from hypotension. The degree of renal failure that develops is varable from
patient to patient, but can be severe enough to require dialysis (2 , 5). Histological
examination of renal tissue from fatal cases of HFS showed evidence of tubular necrosis in
most cases (66).
Bleeding manifestations are apparent during the oliguric phase in approximately 1/3 of
severe cases , and include conjunctival hemorrhage , gastrointestinal bleeding, ecchymosis
(bruising), epistaxis (nose bleeds) and, in rare cases, cerebral hemorrhage (4, 67). Central
nervous system involvement and pulmonary edema have also been observed at this phase in
the most severe forms of disease (4). Fifty percent of fatalities occur during the oliguric
phase, primarly due to hypervolemia, renal failure , pulm?nary edema or a combination
thereof.
Diuresis marks the beginning of convalescence, which may last for several days or
weeks. The diuretic phase is characterized by polyuria (3-6 Uday), improved renal function
and decreased proteinuria. Since non-fatal cases mostly result in complete recovery, the
vascular changes observed during HFS appear to be completely reversible. Complete
recovery is observed in the majority of cases , but there have been some reports of long-term
renal abnormalities following the resolution of HFS (72-74).
2. HPS
Hantavirus pulmonary syndrome is a severe ilness in the majority of cases.
Asymptomatic infection with hantaviruses that cause BPS is not thought to be common
although there have been some observations of individuals who were antibody-positive but
did not experience clinical disease (57). The incubation period of viruses causing BPS is
thought to be approximately 7 to 14 days , slightly shorter than for viruses causing HFS.
BPS is characterized by an initial non-specific febrile period that is similar to that
observed in HFS. However, in BPS the febrile phase is followed by the rapid development
of severe pulmonary edema and respiratory failure , signaled by severe shortness of breath (5
75). Chest radiographs show evidence of pulmonary edema, usually within hours after the
first respiratory symptoms are evident. Supplemental oxygen is required in the majority of
cases , and some patients require intubation and mechanical ventilation.
Death can be extremely rapid in BPS, and is generally attributed to shock and
myocardial dysfunction (75). Autopsies of 14 fatal BPS cases revealed bilateral pleural
effusions in all patients and interstitial mononuclear cell infiltrates in the majority of patients
(75). Recovery from BPS appears to be equally rapid and was until recently thought to be
complete. However, Goade and colleagues now report that many patients experience
significant , long-term sequelae after BPS (76). In a follow-up study of 32 patients who had
BPS caused by SNV or Bayou virus (BA YV), the majority of patients had long-term somatic
and physical complaints including fatigue (89%), decreased exercise tolerance (89%),
shortness of breath (82%), myalgias (82%) and short-term memory loss (55%). In addition
87% of patients demonstrated mild to moderate changes in pulmonary function , with the most
common findings including significantly decreased small airway flow , increased residual
volume and decreased oxygen diffusion capacity. Three patients in that study also
,;:
experienced proteinuria during early convalescence and four others developed proteinuria 2 to
3 years post ilness (76).
3. Antibody responses and diagnosis
The diagnosis of hantavirus infection is most often based on serology. Hantavirus
infection induces high levels of IgM antibodies specific for the N, Gland G2 proteins that are
detectable in serum within the first week of ilness. The IgM response to hantavirus N
antigens is detectable early after the onset of disease (day 1-5) and remains detectable for 2-
months (77-81). The IgG response to the PUU N antigen is detectable early in acute ilness
(1-5 days after onset of disease), while the IgG response to the PUUV glycoproteins is first
detectable in the early convalescent phase (16-30 days after disease onset) (82). In contrast
the SNV glycoprotein-specific IgG response is detectable early in the course of the acute
ilness (81). The levels of both PUU N- and glycoprotein-specific IgG were considerably
increased 2 years after the disease onset, as compared to levels measure in the early
convalescent phase. Hantavirus-specific IgG antibodies are detectable for long periods of
time after the resolution of HFS (80 , 83). Following PUU infections , IgG responses
against the three PUUV antigens remain high several decades after the acute infection (78
82).
The detection of IgM antibodies is the basis for serological diagnosis of acute
hantavirus infection and the differentiation between active and past infections. Indirect
immunofluorescence techniques using native virus grown in Vero E6 cells have been used
historically to detect virus-specific IgM and IgG. More recently, enzyme immunoassays
using both native and recombinant S segment antigens have been developed in varous forms
including a j. capture assay for sensitive detection of PUU virus-specific IgM, which
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facilitates early diagnosis (77 , 84). Since the antibody responses during acute HFS are
usually highly cross-reactive between hantaviruses (85 , 86), diagnosis of the infecting virus
strain requires neutralization assays using convalescent sera or RT-PCR amplification and
sequencing of viral RNA. Newly developed chromatographic assays using highly purified
recombinant antigens appear promising as a tool for rapid diagnosis (87). RT-PCR analysis
has also been used to detect viral RNA in tissues and plasma (88-91).
D. EXPERIMENTAL INFECTIONS IN LABORATORY RODENTS
Definition of the mechanisms involved in the pathophysiology of hantavirus infection
has been hampered by the lack of a suitable animal model that recapitulates the human
disease. Many studies of hantavirus infections in rodents have been carred out, with the
outcome depending on several parameters including the species and age of the rodent, route of
inoculation and strain of virus. Rodents that are susceptible to lethal infection die of a
characteristic meningoencephalitis , rather than a hemorrhagic syndrome affecting the kidneys
or lungs. While these studies may therefore have limited applicability to human infections
they have demonstrated a role for T lymphocytes in both the clearance of the virus as well as
in pathology of infection (92 , 93), a phenomenon that we postulate to occur during human
infection.
Studies using immunocompetent strains of laboratory mice , including BALB/c , CD-
and outbred ICR mice , have demonstrated an age-dependent resistance to infection with a lab-
adapted strain of HTN virus (76- 118). Mice less than two weeks of age infected intracranially
(i.c. ) or intraperitoneally (i. ) developed clinical disease characterized by weight loss , ruffed
fur, hunched posture , limb paralysis and eventually convulsions and sudden death due to viral
meningoencephalitis (37 , 94-96). Virus antigen in those studies was detected in brain , liver
lung, hear, thymus spleen , pancreas and kidney tissues of all mice displaying clinical disease
indicating a systemic infection. Histopathological findings in these mice were characteristic
of a fatal meningoencephalitis with focal necrosis of neurons , perivascular cuffing and
infitration of the meninges with neutrophils and mononuclear cells. However, no
histopathological changes were noted in the lung, liver, hear, thymus , spleen , pancreas or
kidney in BALB/c and CD- l mice , despite widespread infection (94 , 95). Outbred ICR mice
had mononuclear cell infiltrates in the hear and liver and displayed medullary congestion and
hemorrhaging in the kidneys, but there was no evidence of any renal or liver dysfunction as
reflected by laboratory values (96).
Infant nude mice infected with hantavirus displayed identical clinical symptoms and
virus localization , but a delayed onset of disease , suggesting that a mature cellular immune
response may contribute to the pathology of disease (94). However, it is also clear that an
anti-viral T cell response is important in control of infection. Intraperitoneal transfer of
spleen cells from HTNV-immune mice protected infant mice inoculated i.c. 24 hours
previously with a lethal dose of virus , demonstrating a critical role for T cells in the clearance
of virus in these mice (94). Interestingly, in these studies of infant mice it was noted that
survival time was inversely related to age , with death occurrng significantly later in newborn
mice (-c 24 hours of age) than in mice inoculated at 5 or 7 days of age (94 , 95). This
observation was attributed to an incompletely developed immune system in the infant mice
and it was suggested that the cellular immune response may be involved in both
immunopathology and protection against virus infection. The observation that
immunocompetent CD- l mice have earlier disease onset and more fulminant disease than
their nude counterparts , despite identical virus titers in the brain, also supports a role for T
cells in contributing to the pathogenesis of disease (95).
- .
Immunocompetent mice greater than two weeks of age , in contrast to infant mice , do
not exhibit any clinical symptoms and remain healthy following inoculation with HTNV.
Viremia is transient in these mice (92), and the inability to detect viral antigens in any organ
examined 4-6 weeks postinoculation indicates successful clearance of the virus (95). Adult
nude mice , in contrast, become persistently infected following i.p. inoculation. In nude mice
viral antigen is detectable in lung, spleen and brain tissue but the mice show no signs of
clinical ilness. Transfer of spleen cells from immune mice to nude mice 1 day before
inoculation prevented persistent infection , and depletion experiments demonstrated a critical
role for CD8+ T cells in this protection (92).
E. PATHOGENESIS OF HFRS
The pathogenesis of hantavirus infection is not well understood. As mentioned
previously, the lack of a suitable animal model has limited studies aimed at investigating the
pathologic mechanisms underlying hantavirus disease. Many factors are likely to contribute
to the syndromes that result from these infections. Some of these factors are discussed below.
1. Role of virus
The in vivo cellular targets in human hantavirus infections have not been completely
characterized. Many cell types are permssive for hantavirus infection in vitro (97 , 98), but in
most of these the virus replicates to very low titers and requires a long replication period (11
, 99). Adaptation of HTNV to Vero E6 cells resulted in more efficient virus replication,
and is thought to be the most suitable system for virus propagation and infectivity studies (11
98).
In vitro studies have demonstrated that PUUV is able to infect human cell lines
derived from lung (A-427 , WI-38), kidney (A-704), liver (Hep G2) and pharynx (Detroit
562); as well as primary human glomerular cells , umbilical vein endothelial cells (HUC)
and peripheral blood monocytes , thus demonstrating a wide host cell range (98- 100). PUU
replication in most cell types was slow compared to replication in Vero E6 cells (peak
infection at 2-3 weeks vs. 9 days) (98). Primary HUVEC cultures have been shown to be
permissive for many different hantaviruses including HTNV , SEOV , PUUV , and Prospect
Hill virus (PHV) by indirect immunofluroescence using patient sera (101). Hantavirus
antigens were detected in approximately 20% of HUVECs on day 3 post inoculation , and in
100% of cells by day 10 post inoculation. A similar study demonstrated that human
saphenous vein endothelial cells (HSVEC), as well as HUC and CV - 1 cells , can be
infected by HTNV (97). In that study, viral antigens and infectious virus were detected in all
cell types by day 2-3 post inoculation. The amount of infectious virus produced by HSVEC
and HUC cells peaked at day 3 post inoculation and declined gradually over the next 2-
days , and a maximum of 4 logs of virus/ml was produced. No cytopathic effect was observed
in any of the infected cultures during these studies (97 , 98 , 101).
Imunohistochemical studies on human tissues have demonstrated the presence of
viral antigens in PBMC and kidneys during acute HFRS (102 , 103), and lungs during acute
BPS (75 , 104). Yao and colleagues examined PBMC from 110 patients with acute HFRS and
found viral antigens in 50.9% of the samples (102). Antigen were most often detected from
days 4-7 after the onset of ilness , and the percentage of positive cells vared from 2-20%.
Infectious virus was isolated from the plasma and PBMC (B lymphocytes and monocytes) of
these patients early in the course of ilness (day 3-7 of ilness), with the virus recovery rate
from PBMC being twofold greater than from plasma. Other groups have also isolated virus
from the peripheral blood monocytes of rats infected with HTNV (100), and monocytes have
.,.
been suggested to play an important role in the dissemination of virus in humans from the site
of infection to the distant organs such as the kidney.
In rare , severe cases , viral antigen has also been detected in the cerebrospinal fluid
(CSF), consistent with clinical findings of viral meningoencephalitis in these patients (102).
HTNV-specific antibody and soluble HTNV antigen were detected in CSF, and intracellular
HTNV antigens were detected in CSF monocytes in that report. These findings suggest that
in some circumstances , hantaviruses are able to traverse the blood-brain barer and invade the
central nervous system.
Immunohistochemical analysis of kidney biopsy samples from 23 patients with HFS
revealed the presence of viral envelope glycoproteins within the cytoplasm of renal tubular
epithelial cells in greater than 95% of patients (103). Viral antigens were also detected in the
capilary endothelium of interstitial areas and the glomerular capilary walls , although the
staining was generally weaker than in the tubules. Viral glycoproteins were detected in renal
tissues from days 5 to 30 after onset of fever. Pathologic findings in the kidneys included
acute tubular necrosis and interstitial edema characterized by mononuclear cell infiltration and
hemorrhage (103 , 105). However, gross architectural abnormalities in the kidney were
uncommon. Although there is some evidence of renal pathology in kidney biopsies , such as
necrotic tubular epithelial cells that contain viral antigen (103), it is not clear whether necrosis
is a direct result of the virus infection or an indirect result of the immune response to the
vIruS.
It is generally accepted that hantaviruses are non-cytopathic in nature. Numerous
studies have shown that hantaviruses, including HTNV, PUU , SEOV , and PHV, do not have
a direct cytopathic effect on cells infected in vitro (97 , 98 , 101 , 106). However, one study
reported that Vero E6 and renal carcinoma cells infected with HTNV or PHV showed signs of
apoptotic cell death beginning at day 5 post infection (107). Vero E6 cells infected with
HTNV (MOI=0.5) had fragmented DNA as shown by termnal deoxynucleotidyl transferase
(TdT)-mediumted dUTP nick-end labeling (TUNL) assays after 5 days of infection and
fragmented DNA on agarose gels after 7-9 days of infection. The authors suggested that a
decrease in the proto-oncogene protein Bcl- , seen after 6 days of infection with HTNV
might be responsible for the apoptosis observed in this system (107). However, further
support for the induction of apoptosis by hantavirus infection is lacking.
Autopsy samples from individuals with Sin Nombre virus infection showed evidence
of predominant infection of alveolar microvascular endothelial cells as well as the lymphoid
follicles of the spleen (75 , 104). SNV antigen was also detected in the interstitial capilares
of the kidneys , but was absent from the tubular epithelial cells where viral antigen is
predominantly located in HTNV infections (103). These studies demonstrated that infected
cells are structurally intact , thus providing additional evidence that virus infection alone is
insufficient to explain the capilary leakage that is characteristic of HFS and BPS.
Although hantavirus infections appear to be non-cytopathic to the infected cells, the
virus burden in an infected individual may impact the severity of disease. Our laboratory has
quantitated SNV S segment RNA copies by RT-PCR in acute plasma samples from BPS
patients and demonstrated a correlation between copies of viral RNA (vRNA) and severity of
disease (108). In that study, 20 of 26 plasma samples obtained at the time of hospital
admssion were RT-PCR positive for SNV vRNA. When copies of SNV vRNA were
compared to measures of disease severity, a significant positive correlation was found
between vRNA copy number and peak hematocrit levels. In addition, a negative correlation
was found between vRNA copy number and nadir platelet count. Finally the mean S segment
RNA copy number was IloglO higher in the fatal cases than in survivors , although these
values were not statistically significant. Taken together, these data suggested an association
between higher virus burden and more severe ilness during BPS caused by SNV.
2. Role of T lymphocytes
Recent studies of Hantaan and related virus infections in humans suggest a role for the
cellular immune response in the pathology of HFRS and BPS. Studies of acute HFS
patients provide evidence of high levels of activation of the cellular immune response.
Several groups have observed decreases in CD4:CD8 T cell ratios (75 , 109, 110) as well as
higher expression of T cell activation markers , including CD25 , HLA DR and CD71 , in serum
during the febrile and oliguric phases of acute HFRS as compared to convalescence (111).
Examination of biopsy samples revealed the presence of infiltrating lymphocytes
(predominantly CD8+ T cells) in the kidneys of patients with acute PUU infections (105
112), and in the lungs of patients with fatal BPS caused by SNV (75). Although the function
of these cells has not been formally studied, these infiltrating lymphocytes may be activated
virus-specific T cells capable of recognizing virus-infected cells and secreting cytokines and
chemokines. The presence of activated lymphocytes in the kidneys of infected individuals
may result in local or systemic increases in production of these cytokines and other
inflammatory mediumtors which may, in turn , contribute to the capilary leak syndrome and
kidney damage characteristic of HFS.
Additional evidence of T cell involvement in hantavirus pathology comes from a
recent study by Mustonen and colleagues (113), which demonstrated a correlation between
severe disease caused by PUUV infection and the HLA haplotype BS, DR3. This study
included 74 patients with acute PUU infections of varying severity. Of the seven of these
patients who were in shock at the time of admission , all had the HLA B8 , DR3 haplotype.
Nine of the thirteen patients (69%) in the study required renal dialysis were HLA B8+, and
eight (62%) were DR3+. Further, severe acute renal failure was observed in 15 (60%) of the
HLA B8 positive patients compared to only 7 (15%) of HLA B8 negative patients. When
HLA haplotype was compared to other parameters of clinical disease , HLA B8 , DR3 was
found to correlate with several indicators of disease severity. A positive correlation was
observed with maximum levels of serum creatinine and length of hospital stay, while an
inverse correlation was seen with lowest blood pressure. This study showed that a striking
association exists between a paricular HLA type and more severe ilness caused by PUU
infection. A similar relationship has been observed between HLA B35 , DRB1402 and
increased severity of SNV -induced BPS (114). Although these associations are likely to
involve complex mechanisms , these findings suggest a role for T lymphocytes in exacerbating
disease and support a potential role for the cellular immune response in the pathology of both
HFRS and BPS.
Cytolytic T lymphocyte (CTL) lines have been isolated in our laboratory from patients
with BPS caused by SNV infection (115). One CD8+ CTL line was isolated from the blood
of a patient with acute BPS following in vitro culture of the PBMC with low levels of rIL-
This CTL line recognized an epitope on the SNV N protein (amino acids 234-42) and was
shown to secrete IFN-y, but not IL- , following stimulation with anti-CD3. Two additional
SNV N-specific CTL lines that were isolated from a second BPS patient were also reported in
that study (115). One of these was a CD4+ CTL line specific for SNV N372 80, and the other
was a CD8+ CTL line specific for SNV Nl3-39. Interestingly, the latter CTL line was
restricted by HLA B35 , the HLA allele reported to be associated with more severe BPS
caused by SNV infection (114). Additional B35-restricted CD8+ CTL lines have been isolated
from BPS patient PBMC that recognize epitopes on SNV N or G2 proteins (unpublished
data). These data demonstrated a heterogeneous T cell response to SNV Nand/or G2 protein
during acute BPS. These virus-specific CTLs may be involved in both the clearance of virus
and immunopathology, although further studies are needed to define their role during BPS.
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Prospective studies of dengue virus infection in Thai children have demonstrated that
early immune activation contributes to the pathogenesis of dengue hemorrhagic fever (DHF),
which is characterized by a capillary leak syndrome similar to that seen in hantavirus
infection. Plasma levels of soluble tumor necrosis factor receptor type II (TNF-RII), soluble
CDS (sCD8), and soluble IL-2 receptor (IL-2R) were significantly elevated in children with
DHF compared to the more mild dengue fever (DF) (116, 117). Levels of soluble TNF
receptor (sTNF-R) also correlated with the degree of subsequent plasma leakage in children
with DHF. In those studies , CD8+ T cell involvement in immunopathology is suggested by
the increase in sCD8 , sTNF-R and sIL- , which are shed from activated T cells (118-120).
Involvement of virus-specific CTL responses in both the clearance of virus and the
induction of immunopathology has been observed in many virus systems including
lymphocytic choriomeningitis virus (LCMV) (121 , 122), herpes simplex virus (HSV) (123),
rabies virus (124), and respiratory syncytial virus (RSV) (125).
In immunocompetent mice , i.c. inoculation with LCMV results in a fatal central
nervous system (CNS) disease that is attributable to T cell mediumted destruction of infected
cells (126). The fatal CNS disease is prevented if LCMV-specific CTL are transferred
simultaneous with virus inoculation (13). In contrast, nude mice or immunodeficient mice
inoculated in the same manner become persistently infected. Adoptive transfer of LCMV-
immune splenocytes or LCMV-specific CTL clones into these persistently infected mice
induces disease. These experiments clearly ilustrate the dual role of virus-specific T cells in
the protection from and immune pathology of LCMV.
In an experimental model of RSV infection, the transfer of RSV-specific CTL into
infected mice facilitated the elimination of virus from the lungs of the mice, the rate of which
was dependent on the number of transferred T cells (125). However, intravenous injection of
large numbers of virus-specific CTL (8X10 ) was associated with augmented pulmonary
pathology that was fatal in 80% of mice. Histological examination of lung tissues in these
mice revealed increased peribronchiolar infiltration of lymphocytes and monocytes compared
to infected animals that received control influenza-specific T cells or no T cell transfer.
A complex role for virus-specific T cell responses has also been observed in patients
infected with human immunodeficiency virus (HIV). In HIV infected humans , high CTL
precursor (CTLp) frequencies and broad CTL responses have been associated with long-term
non-progression in HIV , suggesting that CTL play an important role in controlling virus
infection (127 , 128). However, in a study of 37 patients with late-stage AIDS (::50 CD4+ T
cells/mm ), Giorgi and colleagues demonstrated that the level of CD8+ and CD4+ T cell
activation , but not virus burden , was associated with a shorter mean survival time (129). In
that study, higher proportions of activated CD4+ and CD8+ T cells expressing the activation
marker CD38 were found in patients who survived.:6 months after CD4+ T cells dropped
below 50/mm , compared to those who survived ::18 months. In addition, CD38 expression
was higher on a per cell basis in patients with shorter survival times. In another study,
elevated levels of CD38+ CD8+ T cells were correlated with increased virus burden in HIV-
seropositive men (130). These observations suggest that virus-specific T cells may contribute
to progression of HIV disease , although the mechanism by which this might occur remains
unknown.
3. Role of cytokines
There are several reports of local and systemic increases in cytokine production during
acute hantavirus ilness. A study of sera from 110 HFS patients collected during the Korean
conflct in the 1950s demonstrated elevations in levels of IL-IB, IF-y and IFN-a in HFS
patients compared with normal controls (131 , 132). Another study of 15 patients with acute
PUUV infections revealed increases in plasma levels of IL-6 and TNF-a in all patients , and
increases in IL- I0 levels in 13 of 15 patients during the acute phase of illness compared to
convalescence- (133). Levels of TNF-a remained elevated at day 8 after onset of fever in 11
patients in this study, while levels of both IL-6 and IL- IO had significantly decreased in all
patients by this time. Increases in IFN -y and IL-8 were also observed in a minority of patients
in that study. Interestingly, levels of TNF-a were found to inversely correlate with the ratios
of the mean blood pressure recorded at admission and at 3 months , suggesting a possible
contributing role for TNF-a in disease severity.
Indirect immunofluorescence studies of renal biopsies from patients infected with
PUU showed increased levels of TNF-a and TGF-B in the kidneys of patients with acute
, which co-localized with inflammatory cell infiltrates , potentially implicating the
infiltrating cells as the primary source of these cytokines (112). That study also demonstrated
increased expression of ICAM- , VCAM- l and PECAM in peritubular regions , which
colocalized with both TNF-a expression and cellular infiltrates. Expression of adhesion
molecules is also increased in the kidney during other immunolopathological renal diseases,
such as murine lupus nephritis (134). Increased expression of adhesion molecules is thought
to contribute to the "stickiness" of the activated endothelium in this model , thus contributing
to leukocyte infiltration.
Preliminary in vitro studies of hantavirus infection have demonstrated that virus
infection alone may induce the expression of cytokines and chemokines by the infected cell
(135). In one study, the mRNA expression of the chemokines MCP- , MIP- , RANTES
and IL-8 was induced in HUEC and primary human monocytes following infection with the
pathogenic ANDV and SNV , but not with the non-pathogenic PHV (135). In this system
expression of mRNA for TNF-a and IFN-y was not induced by virus infection. Another
study demonstrated the induction of RANTES in a human epithelial kidney cell line
(293HEK) and GM-CSF in a fetal lung fibroblast cell line (MRC-5) following infection with
HTNV (136). HTNV infection of primary human monocytes in that study also induced
RANTES secretion and upregulated mRNA expression of the RANTES receptors CCRI and
CCR5. SNV or ANDV infection , in contrast, induced production ofTNF-a from a human
monocytic cell line (TBP- l) and HUVECs , and the production of MCP- l in 293HEK cells.
These studies are preliminary but they clearly demonstrate the potential of varous permssive
cell types to produce cytokines and chemokines as the result of hantavirus infection. The
production of chemokines and cytokines from infected cells could facilitate the recruitment of
lymphocytes and monocytes to the sites of infection , and contribute to the amplification of the
Immune response.
Immunohistochemical analysis of autopsy samples from 6 fatal cases of BPS revealed
increased numbers of cells staining for inflamatory cytokines , including IL- l a, IL- lj3, IL-
and TNF-a (137). These cytokines were detected in cells in both the alveolar walls as well as
in the alveolar spaces. Lymphokines such as IFN-y, IL- , IL-4 and TNF-B were also detected
in small cells in the alveolar walls. Other tissues also contained cytokine-producing cells
including the kidney, liver and spleen.
Although cytokines are a crucial component of an effective anti-viral immune
response, the overproduction of cytokines can have detrimental effects on the host and , in
some cases , exacerbate ilness. The role of cytokines, including TNF- , IFN-y, IL- l and IL-
, in mediumting immunopathology is well documented.
TNF-a is a pleiotropic cytokine, produced primarily by macrophages, that mediumtes
the necrosis of certain tumors in mice following treatment with bacterial LPS. Clinical trials
cared out to assess the potential therapeutic anti-tumor properties of TNF-a in advanced
cancer patients revealed that intravenous infusion of TNF-a resulted in the development of
fever, myalgia, thrombocytopenia and hypotension (138). High doses of TNF-a (205 glm
administered alone or in combination with IFN-y caused severe , sometimes life-threatening
hypotension resulting from peripheral edema which is thought to be due to vascular leak (138
139). Pulmonary toxicity was also reported in that study, as reflected by dyspnea, tachypnea
and severe hypoxemia. TNF-a treatment also caused symptoms such as fever, fatigue
headache and myalgias in the majority of subjects. Many of these constitutional symptoms
and clinical complications are similar to the clinical findings during HFS and BPS.
TNF-a has also been identified as the primary effector molecule in the pathology of
septic shock. Plasma levels of TNF-a were elevated in the plasma of septic shock patients
and in volunteers injected intravenously with bacterial endotoxin (140). In rats and sheep,
administration of recombinant TNF-a recapitulates the symptoms of bacterial septicemia
including severe hypotension and vascular leak (141 , 142). These symptoms are also features
of severe , acute hantaviral diseases. Infusion of monoclonal antibodies to TNF-a prior to
treatment with endotoxin completely protects animals from these effects , implicating TNF-a
as the primary effector molecule involved in mediumting shock in these models (141-143).
Elevated levels of TNF-a have also been reported in the serum of patients infected
with hemorrhagic fever viruses including Dengue virus and Ebola virus (144). Both viruses
are characterized by a capilary leak syndrome , and dengue hemorrhagic fever has many
similar clinical features in common with HFRS and BPS. In Dengue virus infection , TNF-a
was found to be elevated in the serum of patients with the severe disease dengue hemorrhagic
fever (DHF) as well as the milder disease dengue fever (DF) compared to controls (145, 146).
TNF-a, as well as IFN-y and IL- , were found to be significantly elevated in the serum of
patients with fatal Ebola virus infections compared to patients with nonfatal infections and
nonnal controls (144). In an in vitro study of filovirus infection , supernatants from Marburg
virus-infected monocytes induced leakiness in an endothelial cell (EC) monolayer (147). This
effect was inhibited when an anti-TNF-a monoclonal antibody was added, demonstrating that
TNF-a was responsible for the leakiness of the ECs.
TNF-a is also known to have additional effects on ECs , which may provide insight
into the mechanisms that underlie its pathologic effects. Since capilary leak is a hallmark of
hantavirus disease, and endothelial cells appear to be a primary target of hantavirus infection
the effects of TNF-a on these cells are important to consider. TNF-a has been shown to
cause the upregulation of MHC class I molecules as well as adhesion molecules such as
ICAM- l and ELAM- l on the surface of ECs (148). The upregulation of these molecules
contributes to an increased adhesiveness of lymphocytes and other cell types to ECs (149).
TNF-a also induces the production of cytokines by ECs , including IL- , IL- , MCP- l and IL-
, that may contribute to vascular permeability (IL- l) and recruit additional immune cells to
the endothelium (MCP- , IL-8), thus amplifying the inflammatory response.
TNF-a has also been shown to induce morphological changes in endothelial cells
which could account for increases in EC permeability (148). Recombinant TNF-a (rTNF-a)
treatment has been shown to cause a reversible redistribution of plakoglobin , a protein found
in the intra-endothelial cell junctions (147). This redistribution is indicative of the formation
of intra-endothelial cell gaps and correlates with increases in permeability. Changes in
structural proteins such as plakoglobin are likely to result in decreased contact between
neighboring EC, as well as in decreased adherence to the cytoskeleton.
IFN-y has many immunoregulatory effects including activation of macrophages to
enhance phagocytosis and anti-tumor activity, activation of cytolytic T cells and NK cells , and
induction of class I and II MHC molecules on varous cell types. IFN-y has also been shown
to synergize with TNF-a to promote capilary permeability (138). IF-y also appears to
synergize with TNF-a in the activation of endothelial cells. In vitro studies have shown that
treatment of endothelial cell monolayers with a combination of IF-y and TNF-a causes
reversible morphological changes in these cells such that they become plump and retract from
one another, formng dendrite-like processes and intercellular gaps (148). These
morphological changes may contribute to increased permeability. Like TNF- , IF-y also
stimulates the upregulation of MHC class I molecules on endothelial cells which likely results
in enhanced interactions between T cells and the endothelium.
Serum IF-y levels were shown to be significantly elevated in patients with lethal
Ebola virus infections relative to levels in patients who survived infection (144). Similarly, in
studies of acute dengue virus ilness, IF-y was shown to be elevated in the sera of patients
with dengue hemorrhagic fever and dengue fever compared to normal controls (117 150).
Other cytokines such as IL- l and IL-6 have been noted to be elevated during acute
HFS. These inflammatory cytokines can activate T and B cells , and can synergize with
other cytokines and each other to further elevate the immune response. IL- l and IL-
synergize with each other to cause increased production of IL-2 and increased expression of
IL-2R on T cells, which could cause amplification of T cell activation and proliferation (151).
IL- IB is also known to contribute to the activation ofECs and, either alone or in combination
with TNF-a, enhance interactions ofT and B cells with endothelial cells (149 152). IL-
mediumted increases in EC adhesiveness for lymphocytes may result from the marked
upregulation ofICAM- l on EC following IL- l treatment (153). Not surprisingly, IL- IB also
synergizes with TNF-a to produce hemodynamc changes associated with endotoxic shock in
rabbits (154) and has been shown to be elevated in patients with septic shock (140).
IL- , which has been noted to be elevated during HFS (133), was also shown to be
elevated in children with DHF, compared to those with uncomplicated DF (155). In that
study, levels of IL- IO were significantly correlated with the degree of plasma leakage as
measured by pleural effusion index. IL- IO is a potent activator of B lymphoctye
differentiation , and an inhibitor of T cell proliferation (156). IL- 1O is also a potent inhibitor
of IL- 12 production and can thus promote the development of a Th2-type T cell response
(157). During HFS, one could speculate that IL- IO may act as a regulatory cytokine that is
produced to counteract the effects of elevated TNF-a.
4. Role of HLA haplotype
The association of a paricular HLA haplotype with severity of disease suggests a
potential a role for the host cellular immune response in disease pathogenesis. Several
possible explanations for a more severe disease course related to HLA haplotype may be
envisioned. It is possible that individuals with certain HLA alleles have a more vigorous
immune response to the virus, possibly due to the number of potentially antigenic peptides
within the viral proteins that are able to bind to a specific HLA molecule. An extremely
intense immune response could lead to an overproduction of cytokines and inflamatory
mediumtors , as well as continued activation of lymphocytes , that could contribute to
immunopathology. Alternatively, a dysfunctional immune response to the virus could delay
the clearance of the virus and allow enhanced virus replication.
As discussed earlier, a recent study conducted by Mustonen and colleagues (113)
demonstrated an association between the HLA haplotype B8 , DR3 and more severe ilness
following PUUV infection. The same group subsequently noted a significant correlation
between this haplotype and the abilty to detect PUU RNA in the blood and urine of patients
by PCR (158). In this smaller study, PCR positivity was correlated with several measures of
disease severity, including maximum levels of serum creatinine, maximum blood leukocyte
counts , the need for dialysis and the length of hospitalization. The increased ability to detect
viral RNA in patients expressing the HLA B8 , DR3 alleles suggests that these patients may
have a higher virus burden , although levels of viremia were not quantitated in these
indi viduals.
The mechanism underlying the association between HLA and disease severity is not
defined, and is likely to be complex and multifactorial. A polymorphism in the TNF-
promoter region that confers increased TNF-a production (TNF2 allele) was found more
commonly among HFRS patients (42%) than among normal controls (15%) (159). Further
among HFRS patients the TNF2 allele was found in 69% of patients requiring dialysis as
compared to only 15% among patients who did not require dialysis. The TNF2 allele was
also found in all patients who experienced shock. The TNF2 allele differs from the more
common TNFI allele by a single g-'a base change at position -308 relative to the
transcriptional star site of the TNF-a gene. This TNF-a polymorphism has been shown to be
strongly associated with the HLA haplotype Al DR3 (160), the same haplotype associated
with severe HFS following PUU infection. The data from this study do not include
measurements of serum TNF-a levels in patient sera, and the observed differences in the
clinical course of HFS cannot necessarly be attributed to the TNF-a polymorphism. In the
study by Kanerva and colleagues , the presence of the TNF2 allele was significantly correlated
with certain measures of disease severity, including maximum serum creatinine levels and
lowest platelet count. However, since the TNF2 allele is in linkage disequilibrium with the
HLA haplotype B8 , DR3 , it was not possible to determne which factor was most strongly
associated with disease severity. More recent analysis of a larger patient population (n=116)
by the same group revealed that the HLA BS , DR3 haplotype is more strongly associated with
severe HFRS caused by PUU than the TNF2 allele (161). In that study, analysis of varous
clinical parameters of disease severity showed a significant correlation between HLA BS DR3
and maximum creatinine and maximum leukocyte count during the course of treatment. In
contrast, no correlations were observed between clinical measures of disease severity and the
possession of the TNF2 allele , suggesting that the HLA haplotype BS , DR3 is a more
important factor in the severity of HFS caused by PUUV infection.
The extended haplotype Al DR3 has also been associated with autoimmune
diseases including systemic lupus erythamatosus (SLE), celiac disease , multiple sclerosis
thyroiditis , Addison s disease , type- l diabetes melltus and chronic active hepatitis. In most
of these autoimmune diseases , inappropriate activation of T lymphocytes is thought to
contribute to disease (162 , 163). In individuals with active SLE, increased percentages of
activated CD4+ T cells are found in the circulation , but these cells show depressed
proliferative responses to mitogens in vitro. In contrast , CDS+ T cells from SLE patients did
not express activation markers and were found to respond normally to mitogen stimulation
although overall numbers of circulating CDS+ T cells were significantly lower than in normal
controls or individuals with inactive SLE (162). Activated T lymphocytes are also thought to
playa key role in the pathology of multiple sclerosis (MS), since CD25+ T lymphocytes were
found in the cerebrospinal fluid of patients with active MS, but were absent in patients with
chronic MS or other neurological diseases (163). Although it is clear that T cell responses
were altered in patients with these autoimmune conditions, the specific mechanisms
responsible for the HLA BS , DR3 associated predisposition to autoimmunity have not been
defined.
Individuals who cary this haplotype have also been shown to have abnormal T cell
responses in vitro. Studies of healthy young adults carying the AI , BS , DR3 haplotype
demonstrated that PBMC from these individuals had impaired proliferative responses to
stimulation with mitogens as compared to controls (164 , 165). Mitogen stimulated PBMC
from individuals with this haplotype were also shown to secrete less IL-2 than controls , and
this was thought to account for the limited proliferation. It has also been noted that the
secretion of other cytokines , including IL- , IL-5 and IFN-y, is significantly impaired in these
individuals. However, no differences were noted in production of IL- , IL-6 or IL-
between HLA B8/DR3+ and HLA B8/DRT individuals (166, 167). Another study has shown
that expression of the early activation marker CD69 following PRA stimulation is also
defective in lymphocytes from HLA BS, DR3+ individuals.
In mice , it is clear that differences in MHC haplotype impact the level of immune
responsiveness to hantaviruses. A recent study examined humoral and Th cell responses in
mice following immunization with a recombinant PUU N protein (16S). This study showed
that H- mice had the strongest antibody responses following immunization, followed by H-
and, lastly, H- mice. The same hierarchy was observed for T cell proliferative responses
following in vitro restimulation with pools of overlapping PUUV N peptides. This study
ilustrated that the immune response to hantavirus infection is impacted by the MHC
haplotype of the infected mouse , probably due to differences in the ability of paricular HLA
alleles to present determnants from the hantavirus proteins.
F. HANTAVIRUS VACCINES
Currently there is no effective vaccine against hantavirus infection that is widely
administered. Several vaccines utilizing inactivated HTNV and SEOV virus grown in cell
culture or mouse brain have been tested in humans in Asia (169- 171). These vaccines have
been shown to be safe and to elicit neutralizing IgG responses. However, antibody responses
in vaccine recipients tended to be low and transient with -(50% of vaccinees retaining
measurable antibody responses one year after the initial vaccination in one study (169). Other
strategies have employed vaccinia virus or baculovirus systems to express recombinant
hantavirus antigens (172- 174). Inoculation with a recombinant vaccinia virus expressing the
HTNV M genome segment was shown to elicit neutralizing antibody responses in mice (173
174) and to protect hamsters against subsequent infection with native HTNV (173). Passive
transfer of monoclonal antibodies to the glycoproteins also protected hamsters from challenge
with HTNV , suggesting that neutralizing antibody responses may be sufficient to protect
against infection (173). Recombinant vaccinia viruses expressing the HTNV S genome
segment appeared to be less effective in both eliciting antibody responses in mice and in
protecting hamsters against HTNV infection. However, immunization with a recombinant
baculovirus expressing the HTNV S segment was shown to be effective in eliciting antibody
responses as well as in protecting hamsters against subsequent infection (173). In a recent
clinical trial in humans , subcutaneous (s. ) inoculation with a vaccinia virus expressing the
HTNV M segment elicited neutralizing antibody (nAb) responses in 72% of vaccinia virus-
naIve volunteers , and 26% of vaccinia virus-immune volunteers (175).
The cellular immune response has also been shown to playa role in protection against
hantavirus infection. In one study, passive transfer of spleen cells from mice immunized with
baculoviruses expressing HTNV S (rNP) or M (rEnv) segments to suckling mice conferred
partial protection and prolonged survival time after lethal HTNV challenge. This protection
was also noted when monoclonal antibody or T cell-enriched spleen cell fractions from rNP
immunized mice were transferred, indicating a role for both T lymphocytes and antibody
responses in the protective effect. Phase I and Phase II clinical trials in humans also resulted
in the development of CD4+ T cell responses following s.c. inoculation with a vaccinia virus
expressing the HTNV M segment (175).
Recently, portions of the nucleocapsid protein from PUUV were expressed in hepatitis
B virus core-derived chimeric proteins , and immunization with these paricles was shown to
protect bank voles against subsequent infection with a different strain of PUU (176). Naked
DNA vaccines have also been recently developed. DNA constructs expressing the M or S
genome segments of SEOV were tested for immunogenicity in BALB/c mice and Syrian
hamsters. Inoculation with DNA vaccines expressing either the M or S segment resulted in
the production of virus-specific antibody in mice , with gene gun administration proving to be
the most effective route of inoculation (177). When Syrian hamsters were vaccinated with
these constructs and subsequently challenged with SEOV , only the construct expressing the M
segment effectively conferred protection against virus challenge , although both constructs
elicited antibody responses in the animals.
Most of the immunization strategies developed thus far focus on the development of a
neutralizing antibody response, and this response has been demonstrated to be effective in
some systems. However, the studies of humans inoculated with inactivated hantavirus
vaccines demonstrate that the antibody response to these virus formulations may be low and
transient. Additional studies in human subjects wil be required to determne whether other
vaccine strategies wil result in the development of more long-lasting anti-viral antibody
responses in humans. Ultimately, the development of a vaccine capable of inducing both 
cell responses as well as neutralizing antibody responses may be required to insure long-lived
protection against hantavirus infection.
G. THESIS OBJECTIVES
HFS and BPS have been suggested to be caused in par by immunopathologic
mechanisms, including the actions of CD8+ and CD4+ T lymphocytes. We hypothesize that a
combination of very intense virus-specific T cell responses and high virus titers in infected
individuals leads to the development of an immunopathologic state that may contribute to
hantavirus disease. T lymphocytes may playa dual role during hantavirus infection , as they
do in many other viral infections. It is likely that an effective T cell response is critical for the
clearance of virus. However, it is also possible that an extremely robust T cell response may
lead to a relative "over-activation" of the immune system, which could contribute to
immunopathology. Quantitative analyses of virus-specific T cell responses during acute
hantavirus infections have not been performed and wil be critical in determining whether a
correlation exists between levels of T cell activation and disease severity.
The overall goal of the studies discussed here is to gain an understanding of the scope
and characteristics of the memory T lymphocyte response to Old World hantavirus infections
by identifying dominant viral proteins and T cell epitopes that are targeted by the CTL
response in immune individuals. Prior to the present studies , no formal analyses of T
lymphocyte responses to these viruses had been performed. The studies described here not
only provide the first qualitative and quantitative information regarding virus-specific human
T cell responses to HTNV and PUU, they also provide the necessary framework to conduct
quantitative studies of specific T cell responses during acute ilness , using techniques such as
MHC-peptide tetramer analysis and intracellular IFN-y staining. Such quantitative analyses
of the magnitude and dynamics of the virus-specific T cells responses during acute infection
wil be critical to the understanding of the role that T cells play in the clearance of virus and in
the pathology of disease.
Further, the identification of viral proteins and T cell epitopes that are targeted by the
human immune system may impact the design of effective vaccines that can elicit both T
lymphocyte responses and antibody responses. The specific objectives of this thesis are as
follows:
1. Characterization of the memory T cell responses in indi viduals with sub-clinical
laboratory-acquired infections with HTNV.
2. Characterization and quantitation of memory T cell responses in individuals who had
clinical , naturally-acquired infections with PUUV between 1984 and 1995.
3. Design and optimization of a quantitative , competitive RT-PCR strategy to measure viral
RNA levels in patient plasma during acute PUU infection.
CHAPTER II
MA TERIALS AND METHODS
A. PBMC Donors.
Hantaan virus study: Donors were American scientists who became infected with the HTNV
10- 15 years prior to the study. Infections were subclinical and were confirmed by detection
of HTNV -specific immunoglobulin in the serum. The HLA types of these donors are as
follows: Donor A: AI , A2 , B35 , B51 , Cw4 , Cw7 , DR2 , DR3, DQ2 , DQ6 and DRw52.
Donor B: A2 , All , B39 , B60 , Cw3 , Cw12 , DR4 , DR9, DQ3 and DRw53. Donor C: AI , All
, B51 , Cw7 , Cw15 , DR7 , DRll , DQ3 , DRw52 and DRw53.
PBMC were purified by Ficoll-Hypaque density gradient centrifugation. Buffy coats were
recovered and mononuclear cells were resuspended at 5-8XI0 /ml in RPMI 1640/20%
FBS/I0% dimethyl sulfoxide (DMSO) and cryopreserved until needed.
Puumala virus study: Donors were Finnish individuals who had clinical HFS caused by
PUU infection between the years 1984 and 1995. Diagnosis of PUU infection was
confirmed by serological detection of PUUV -specific antibodies using a commercially
available ELISA kit. PBMC were purified using Vacutainer CPT tubes (Becton Dickinson).
Cells were resuspended at 1-2XI0 /ml in RPMI 1640 supplemented with 20% FBS (Sigma,
St. Louis , MO), 2mL L-glutamine , 50 U/ml penicilln , 50 /lg/ml streptomycin , and 10%
DMSO and cryopreserved until use. The age , year of infection and Class I HLA haplotypes
of the donors are shown in Table IV-
B. B lymphoblastoid cell lines (BLCLs).
PBMC (1-4XI0 ) were cultured in RPMI 1640 , supplemented with penicilin , streptomycin
glutamine , HEPES and 20% FBS in the presence of 1:3 dilution of Epstein-Bar virus from
B95-S cells (ATCC) in 24-well flat-bottom plates (Costar), as previously described (17S).
Cyclosporin A was added at IJ.g/ml to inhibit proliferation of T lymphocytes. Once
transformed, BLCLs were maintained in RPMI 1640/20% FBS and passaged three
times/week.
C. Recombinant vaccinia viruses expressing hantavirus proteins.
Recombinant vaccinia viruses expressing HTNV genes were constructed as described (173)
and were kindly provided by Dr. Connie S. Schmaljohn. The recombinant vaccinia viruses
used in this study were derived from the WR strain of vaccinia and express either individual
HTNV genes encoding Gl , G2 or nucleocapsid (denoted vac- , vac-G2 and vac-
respectively), or all three genes simultaneously (denoted vac-Gl+G2+N).
Recombinant vaccinia viruses expressing PUUV genes were constructed as described
(Masanori Terajima, manuscript in preparation), and express whole or parial PUU genes
encoding N , Gl , G2Bs (amino acids 1-256) or G2/Sm (amino acids 227-490).
D. Synthetic peptides.
Seventy (70) HTNV nucleocapsid peptides were synthesized that spanned the entire published
sequence of the HTNV nucleocapsid protein (15)(Accession#MI4626). Peptides were 15
amino acids in length and overlap by 9 amino acids. Seventy (70) PUU nucleocapsid
peptides were synthesized as above based on the published sequence of PUU strain K27
(179) (Accesion#LOSS04). N protein peptides from other hantavirus strains were synthesized
based on published sequences and included SEOV (18) (accession#M34881), SNV (180)
(accession#L37904), PHV (181) (accession#M34011), ANDV (8) (accession#AF004660),
PUUV strain Hallnas Bl (182) (accession#M32750), NYV (183) (accession#U47135), and
DOBV (184) (accession#L41916) and SNVstrain CC107 (185) (accession#L33683). Peptides
were synthesized at the Protein Chemistry Core Facility at the University of Massachusetts
Medical School using an automated Rainin Symphony peptide synthesizer.
E. In vitro stimulation of PBMC.
Hantaan virus study: 5X10 / PBMC were plated in 1 ml AIMV/ 10% human AB serum 
a single well of a 24-well plate (Costar). A gama-irradiated, inactive HTNV preparation
was added at a 1:160 final dilution. HTNV was grown in Vero E6 cells (ATCC) and purified
as described (11). The purified virus was then y-irradiated (8x10 Rads) to inactivate the
virus. Inactivation of the virus was confirmed by plaque assay. Recombinant human IL-
(20U/ml) was added on day 4 or 5 in 1 ml of fresh AIM /10% human AB serum and the
medium was replenished every third day thereafter. Bulk culture Cr-release assays were
performed between days 7 and 14 of culture. Donor A PBMC was restimulated on day 7 with
inactivated HTNV (1:160) and 2-3XI0 irradiated autologous PBMC in order to reduce
non-specific background lysis. rIL-2 was added to these cultures on day 11 and cultures
tested on day 14.
Puumala virus study: 7X10 PBMC were resusupended in 1 ml of AIM-V medium
supplemented with 10% human AB serum. The PBMC were stimulated with 20 III of purified
PUU (strain K27 , kindly provided by Connie S. Schmaljohn), grown in Vero E6 cells and
purified as described (11). Recombinant human IL-2 (5 U/ml) was added on day 5-6 of
culture in fresh AIM-V/IO% human AB serum and the medium was replenished every third
day thereafter. Bulk Cr-release assays were performed on day 7-8 of culture. In some
cases , cultures were restimulated once with 2X10 irradiated autologous PBMC and 20 l of
purified PUUV in fresh AIM-VIlO% HuAB serum supplemented with 10 U/ml rIL-2. Cr-
release assays were performed on restimulated cultures 7-8 days post-restimulation (Day 14-
15 of culture). Cultures were maintained and all experiments were performed in a biosafety
level 3 (BSL3) laboratory according to standard BSL3 guidelines.
F. CTL lines.
HTNV -specific or PUUV -specific CTL lines were established by limiting dilution plating as
described (186). In vitro stimulated PBMC were plated at 1 , 10 or 30 cells/well in a 96-
well , round-bottom plate (Costar) in 0.2 ml AIM/I0%FBS and stimulated using anti-CD3
antibody (12F6) and gamma-irradiated allogeneic PBMC as feeder cells. Medium was
replenished every three days and wells were restimulated with anti-CD3 and y-irradiated
feeder cells every 14 days. Individual wells were tested for recognition of target cells
expressing HTNV or PUU proteins in a Cr-release assay and positive wells were expanded
and restimulated as described above. Surface expression of CD4 and CD8 were determned
by flow cytometry using fluorescein isothiocyanate-conjugated antibodies (Becton
Dickinson). HLA restriction of individual CTL lines was determned using partially HLA-
matched BLCL targets infected with a vaccinia virus recombinant expressing HTNV or
PUU N. Fine specificity of CTL lines was determned using overlapping synthetic peptides
that span the HTNV or PUU N protein and subsequent N- and C-termnal peptide
truncations.
G. Preparation of target cells.
Virus- infected targets: Autologous or allogeneic (for MHC restriction analysis) B
lymphoblastoid cell lines (BLCL) were infected with recombinant vaccinia viruses at an
MOI=15 for 60 mins at 37 C. The cells were then diluted in 1 ml ofRPMI 1640/10% FBS
for an additional 12-16 hours. Target cells were then labeled with 0.25 mCi of Cr for 60
mins at 37 C. Following labeling, the cells were washed 3 times and resuspended at 1-2XI0
cells/ml in RPMIIO% FBS.
Peptide-pulsed targets: Uninfected BLCL were Cr labeled as described above. Labeled
cells were incubated with the indicated concentrations of peptide in 96-well round-bottom
plates at 1-2XI0 /well for 30 mins at 37 C before addition of effector cells. The peptides
remained in the wells for the duration of the assay.
H. Cr-release cytotoxicity assay.
In vitro stimulated effector cells were added to 2X10 Cr-labeled target cells at the indicated
E:T ratios. For CTL assays using synthetic peptides , T cell lines or clones were added to 1-
2X10 Cr-labeled, peptide-pulsed targets at an E:T ratio of 10:1 (unless otherwise specified).
Spontaneous release was measured in wells containing target cells and medium, and
maximum release was measure in wells containing target cells and 5% Renex. Plates were
incubated for 4.5 hours at 37 C, supernatants harvested (Skatron Instruments , Sterling, V A)
and specific lysis calculated as ((experimental release-spontaneous release)/(maximum
release-spontaneous release)XI00). All targets were tested in duplicate or triplicate wells.
All experiments were performed at least twice. Negative controls included target cells
infected with wild type vaccinia virus or unpulsed target cells. Spontaneous lysis was -=25%
in all assays.
I. Proliferation Assays.
PBMe. Convalescent PBMC from PUUV-immune individuals were stimulated in vitro with
irradiated PUUV at the indicated dilutions at 37 C. PBMC were seeded at 1.5X10 /well in
96-well round bottom plates in replicates of 5. Six days post-stimulation , 50 1-1 of supernatant
was collected from each well for analysis of cytokine secretion. The wells were then pulsed
with eH)-thymidine (1.25 I-Ci/well) and incubated for an additional 16 hours. The highest
and lowest counts per min (CPM) values were discarded and the remaining 3 values were
averaged. Stimulation index was calculated as CPM (virus stimulation)/CPM (medium
control).
J. Cytokine analysis by ELISA.
Supernatants were collected from cultures of PBMC stimulated with y-irradiated PUU (Day
6) or T cell clones stimulated with peptide-pulsed autologous BLCL (48 hours), as described
above. Quantitation of cytokines in supernatants was performed using commercial kits
(Endogen) according to the manufacturer s instructions.
K. ELlS POT assay for single cell IFN-y secretion.
ELISPOT assays were performed as described (187). Briefly, 96-well filtration plates (MAIP
S 45; Milipore, Bedford, MA) were coated with 15 I-g/ml mouse anti-human IFN-
monoclonal antibody (mAb) (clone NIB42 , Pharmingen, San Diego, CA). PBMC were
incubated for 24 hours in RPMI/lO% FBS with no stimulation and added at 2X10 cells/well
in RPMI 1640/10% FBS. Peptides were added at 25 I-g/ml and plates were incubated for 18-
20 hours at 37 C. Following extensive washing (6X with PBS/0.5% Tween), biotinylated
mouse anti-human IFN-y mAb (clone 4S. , Pharmingen) was added to each well and plates
were incubated for 2 hours at room temperature. Plates were washed extensively (8X with
PBS/0.5% Tween) and then a 1 :400 dilution of streptavadin alkaline phosphatase was added
and plates were incubated at room temperature for 45 mins. Substrate (3-amino-9-ethyl-
carbazole/0. 15%H 02; 200 l) was added to each well and plates were incubated for 10 mins
at room temperature. Precursor frequency was calculated as #visible spots/# total cells per
well. Experiments were performed in triplicate.
L. TCR VB expression by PCR.
Total cellular RNA was isolated using Ultraspec total RNA isolation reagent (Biotecx
Laboratories , Inc , Houston , TX) according to manufacturer s instructions. cDNA was
synthesized using random hexamer primers and Moloney murine leukemia virus reverse
transcriptase (Promega, Madison , WI). The cDNA was then aliquoted into 26 tubes , each
containing a single T cell receptor (TCR) VB-specific primer and a constant region-specific
primer. Each tube also contained primers specific for B-actin as an internal control. PCR was
performed for 25 cycles as follows: 95 C for 1 min. , 55 C for 1 min. , 72 C for 1 min (1.5 min.
denaturing step used for the first cycle). PCR reaction products were resolved on a 5%
polyacrylamide gel and visualized by ethidium bromide staining.
M. Plasmid construction for quantitative RT -PCR.
Construction of competitor plasmid. To construct the competitor S segment RNA
transcription vector, we stared with the pFIR2+ 118 plasmid (108), which contains the Sin
Nombre virus S segment (nt 42-309) plus an additional 118 base pairs (bp) from the
0X174/HaeliI molecular weight marker. In order to use this competitor plasmid for PUU-
specific RT-PCR , we engineered PUUV-specific primer binding sites at the ends of the SNV
S segment as follows. The pFIR2+ 118 plasmid was first digested with HaelII for
linearization and the SNV S segment (including the 118-bp insert) was amplified by PCR
using hybrid primers containing both SNV - and PUU -specific regions. The PUU -specific
portions of the primers was chosen from a conserved region of the PUUV S segment
(Sotkamo strain; accession #X61035) and span nucleotides 63-86 (forward primer) and 286-
309 (reverse primer) of the S segment (underlined regions below). The SNV specific portions
of the primers span nucleotides 87-97 (forward) and 275-286 (reverse) of the SNV S segment
(accession #L25784). The primer sequences were as follows: forward primer (PUUSNV):
5' - CCA AGA GGA TAT AAC CCG CCA TGA ACA ACA ACT CG- ; reverse primer
(PUUSNVR): 5' GTG GTC ATC AGGTTC AAT CCC AGT TGG ATC AAC AG- . The
resulting 388-bp PCR product was cloned into the pCR2. 1 vector using the TA Cloning kit
(Invitrogen , Carlsbad, CA), according to the manufacturer s instructions. A plasmid that
contained the PCR product in the same orientation as the lacZ gene , designated FIR2+ 118-
was confirmed by restriction enzyme digestion and selected to produce negative-stranded
RNA by in vitro transcription.
Construction of positive control plasmid. To generate positive control RNA for the RT-PCR
assay we used a plasmid, pSP72- , which contains the cDNA for the PUU S segment (strain
K27 , accession #L08804) inserted into the EcoRI site within the multiple cloning site of
plasmid pSP72. Since we were unable to efficiently transcribe RNA from the full-length
linearzed template , we truncated the PUU S segment in pSP72- 1 via restriction enzyme
digestion with Acel. This digestion removed the 3' end of the S segment cDNA leaving
nucleotides 1-360. The resulting plasmid was then religated and was designated pSP72- 1tr.
N. In vitro transcription.
The FIR2+ 118-8 (competitor) and pSP72- ltr (positive control) plasmids were digested with
BamHI and EcoRV enzymes respectively. The linearzed templates were used for in vitro
transcription , which was carred out using the Ribomax Large Scale RNA Production System
- T7 or -SP6 (Promega) according to the manufacturer s instructions. The competitor RNA
was transcribed from the T7 promoter and the positive control from the SP6 promoter. The 
vitro transcribed RNA was treated with RQI-RNase free DNase and purified using Ultraspec
total RNA isolation reagent (Biotex Laboratories , Houston , TX). Spectrophometric analysis
(OD 260/280) was used to assess the concentration and purity of the RNA. The RNA was
aliquoted and stored at - C until use.
Figure II- I: Expression plasmids used for in vitro RNA transcription. PSP72- ltr (positive
control plasmid) and FIR2+ 118-8 (competitor plasmid).
o. RNA Extraction
RNA was extracted from 140 I.d of human plasma using the QIAamp Viral RNA kit (Qiagen
Valencia, CA) according to the manufacturer s instructions. The RNA was eluted in 50 III of
diethylpyrocarbonate-treated water and stored at - C until use.
P. RT-PCR.
The PCR primer sequences were designed to bind to relatively conserved regions of the
PUU S segment based on sequence alignments of the S segments from multiple PUU
strains. The PCR primers were identical to the PUU -specific portion of the hybrid primers
described in section N of the Methods. The primer sequences were as follows: upstream
primer (PUU6386): 5' CCA AGA GGA TAT AAC CCG CCA TGA- ; downstream primer
(PUU 286309): 5' -GTG GTC ATC AGG TIC AAT CCC AGT- . The expected sizes of the
PCR products were 247-bp and 365-bp for the positive control (or viral RNA) and competitor
respectively. RT-PCR reactions were carred out in single tubes using the EZ rTth RNA PCR
kit (Perkin-Elmer, Foster City, CA). The PCR reaction consisted of the following: IX EZ
Buffer 50mM bicine , 115 mM potassium acetate , 8% (wt/vol) glycerol (pH 8.2)), 0.3 mM of
each dNTP, 5 U of rTth polymerase , 2.5 mM Mn(OAch, and 1 pmol/Ill of each primer.
Reverse transcription was cared out at 55 C for 30 min. , followed by incubation at 94 C for
2 min. PCR was carred out for 40 cycles as follows: 94 C for 45 sec. , 55 C for 45 sec. , and
C for 45 sec. The final cycle was at 72 C for 7 min. PCR products were resolved on a 2%
agarose gel and stained with ethidium bromide. For quantitative RT-PCR, serial dilutions of
the competitor negative-stranded RNA (known concentrations in RNA copy numbers) were
added to each reaction tube in addition to the unknown vRNA or the positive control RNA.
The viral RNA copy number was calculated by comparng the intensity of the viral RNA band
to that of the competitor band. When the intensities of the two bands are equivalent, the
concentration of RNA is equivalent.
CHAPTER III
HUMN MEMORY CTL RESPONSES TO HTNV INFECTION: IDENTIFICATION
OF VIRUS-SPECIFIC AND CROSS-REACTIVE CDS+EPITOPES ON
NUCLEOCAPSID PROTEIN
In our initial studies of human T lymphocyte responses to hantaviruses that cause
HFS , we examined the PBMC from three individuals who had previous laboratory-acquired
infections with HTNV. HTNV , the prototype member of the hantavirus genus , is known to
cause a relatively severe form of HFRS. These individuals, however, had sub-clinical
infections with no evidence of the renal or circulatory abnormalities that are characteristic of
HFS , and no indication of capilary leakage. HTNV infection was confirmed in these
subjects by detection of HTNV -specific immunoglobulin in the sera.
The goals of this initial study were to identify the viral proteins that were targeted by
T lymphocytes in these individuals , to identify specific CTL epitopes on one or more viral
proteins , and to assess whether the CTL responses in these individuals were cross-reactive
with other members of the Hantavirus species. In general , little is known about the specific
cellular immune responses to hantavirus infection. Our laboratory has previously described
several CD8+ and CD4+ N-specific CTL lines that were isolated from the peripheral blood of
patients with BPS caused by SNV infection (115). The CD8+ CTL lines isolated in this study
were largely SNV-specific , while the CD4+ CTL line was cross-reactive with other
hantaviruses. Although recovery from hantavirus infection is thought to confer immunity
against the infecting virus, it is not known whether recovery from infection with one
hantavirus confers some level of protective immunity against other hantaviruses.
Alternatively, it is possible that pre-existing immunity against one hantavirus could
predispose an individual to a hyper-activation of the immune system upon infection with a
new hantavirus. This situation could potentially lead to the development of
immunopathology. This is an important question, paricularly in geographic regions where
more than one hantavirus co-circulate (188). An understanding of the characteristics of the T
cell response to HTNV , as well as other hantavirus infections , wil provide insight into the
mechanisms underlying the pathology of hantavirus-induced HFS and BPS. In a more
practical sense , this knowledge may also contribute to the design of effective vaccines and
wil provide information necessary to construct the tools by which to study the dynamcs of
the T cell response during acute hantavirus infections.
A. Protein specificity of CTL lines from HTNV -immune donors.
PBMC from three HTNV-immune donors were stimulated in vitro for 7-14 days with
an inactivated HTNV preparation. These bulk cultures were then tested for specific lysis of
autologous BLCL target cells infected with vaccinia recombinants expressing one or more
HTNV proteins. Stimulated PBMC from donor A recognized target cells expressing the
nucleocapsid (N) protein , including those infected with vac-N and vac-G 1 +G2+N (Figure il-
1). Lysis of target cells expressing the N protein was relatively low (18-27%) but was
consistently higher than killng of target cells infected with wild type vaccinia virus (c:7%).
PBMC from donor B consistently displayed low-level lysis of target cells expressing the G 
glycoprotein (vac- , vac-Gl+G2+N) (Figure III- I). Donor B PBMC also displayed low
level recognition of the nucleocapsid protein , although the killing of targets expressing G 
was always higher than that of targets expressing N. PBMC from donor C consistently
recognized target cells expressing the HTNV N protein (Figure III- I). In summary, the above
data show that the PBMC from donors A and C recognized target cells expressing the N
protein while PBMC from donor B lysed target cells expressing G 1. We were unable to
detect responses specific for the G2 glycoprotein in the PBMC from any of these donors. 
is possible that memory T cell responses specific for G2 protein are present in these
individuals but are not prevalent enough to detect following short-term stimulation. CTL
responses to the G2 protein of SNV have been detected in our laboratory and CDS+ G2-
specific CTL lines have been isolated, demonstrating that the SNV G2 protein contains
immunogenic epitopes. It is likely that other hantavirus G2 proteins also contain CTL
epitopes as well.
When T cell lines were cloned from the PBMC of these donors , the CTL lines isolated
from each donor were specific for the protein that was consistently recognized in bulk culture.
Results for representative T cell lines isolated from these donors are shown in Table III-
Both CD8+ and CD4+ T cell lines specific for the N protein were isolated from PBMC from
donors A and C. In contrast, only CD4+ T cell lines specific for the G 1 glycoprotein were
detected in the PBMC from donor B. Although low level recognition of target cells
expressing the N protein was seen in the bulk PBMC cultures from donor B , we were not able
to isolate N-specific cell lines from this individual. These data demonstrate that HTNV-
specific T cell responses are readily detectable in the PBMC of these immune individuals and
that responses are directed primarly against the viral N protein and the Gl glycoprotein. The
bulk culture responses as well as the specificity and phenotype (CD4/CDS) of the virus-
specific T cell lines vared between individuals.
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Figure III- I: Bulk culture recognition of HTNV proteins by in vitro-stimulated PBMC.
Vaccinia viruses used to infect target cells express individual HTNV proteins or a
combination of proteins as indicated on the x axis. Lysis of target cells infected with wild-
type vaccinia virus served as a negative control. Err = 80:1. Data from a representative
experiment is shown.
Table III 1. Cytotoxicity of CD4+ and CDS+ T cell lines isolated from HTNV -immune donors
Donor Cell Line Phenotype % Specific Lysis
vac-G 1 vac-G2 vac-
70.CDS
CD8
IO- CD8 53.
1O- CD8 1.6 58.
CD4 0.4 66.
CD4 3.4 61.4
vac
1.9
1.6
CD4 33. 0.3 0.4
lO-C 11 CD4 30.
1O- CD4 25.4 2.4 1.0
lA- CD8 87.
3A- CD8 60.
3A- CD8 1.0 44.
3A-ClO CD8 68.
3A- CD8 84.
3A- CD4 47.
EIO CD4 40.3
CD4 55.
Data from representative cell lines are shown. EfT ratios vary from 20: 1 to 50: 1.
Celllines were 95% CD4 or CD8 by flow cytometry.
Specific lysis values 10% above background were considered positive and are underlined.
(- ) Target not tested.
B. Peptide specificity of CDS+ CTL lines from HTNV -immune donors A and C.
To identify the specific peptide on the N protein recognized by the CD8+ CTL lines lill
il-
'1;
'18
Pil
III
each cell line was tested in Cr release assays against target cells pulsed with a series of
seventy overlapping peptides spanning the entire HTNV nucleocapsid protein. The 15-mer
peptides recognized by the CD8+ CTL lines of the two donors are shown in Table Ill-
Interestingly, all N-specific CD8+ CTL lines isolated from donors A and C recognized one of
two 15-mer peptides on the nucleocapsid protein. CTL lines 3-G7 and IO-E2 from donor A
Iii
III
\'1
Iii
:1:
and 3A-G3 from donor C recognized target cells pulsed with a peptide that is located at the
!I:
amino termnus of the N protein and spans amino acids 7-21 (LQREINAHEGQLVIA). CTL
line l-C8 from donor A and lines lA- , 3A-B8, 3A-C4 and 3A-ClO from donor C
recognized target cells pulsed with a peptide that is located at the extreme carboxy termnus 
the protein and spans amno acids 416-429 (VKVKEISNQEPLKL). Subsequent screening of
numerous other cell lines from these two donors resulted in the isolation of additional CTL
lines that recognized the same pep tides (data not shown).
Once the nucleocapsid peptides (15-mers) recognized by the CTL lines were
identified, sequential N- and C-termnal truncations of the peptides were synthesized and
tested in Cr release assays. The patterns of peptide recognition of representative clones
from each donor are shown in Figures III-2 and Ill-3. The clones specific for N peptide 7-
(donor A: 3-G7, IO-E2; donor C: 3A-G3) were all found to recognize a minimal9-mer
peptide spanning amino acids 12-20 (NAHGQL VI). A representative CTL line from each
donor is shown in Figure III-2A&C. These cell lines required comparable peptide
concentrations for target cell recognition (Figure III-3A), suggesting that the TCRs expressed
by these cell lines have comparable affinity for the peptide/MC complex. The CTL lines
specific for the N peptide 416-429 (donor A: l-C8; donor C: lA- , 3A- , 3A- , 3A-CIO)
were all found to recognize a minimal 9 amino acid epitope at the extreme carboxy termnus
of the protein spanning amino acids 421-429 (ISNQEPLKL). Data from representative CTL
lines from both donors are shown in Figure III-2B&D. These CTL lines also required similar
peptide concentrations for target cell recognition with the exception of CTL lines lA-B7 and
3A- , which required a slightly higher peptide concentration for optimal target cell
recognition (Figure III-3B).
Table III-2. Nucleocapsid peptide recognition of CDS+ CTL lines
Donor A CTL Line Amino AcidsC8 416-429
10- E2
Donor C CTL Line
lA-
3A-
416-429
416-429
3A-
3A-ClO
416-429
416-429
3A-
A. Donor A 3-
vac- N
vac
N 7-21 LQREINAHGQLVIA
N 7-20 LQREINAHGQLVI
N 7- 19 LQREINAHGQLV
N 9- REINAHGQL VIA
N 11- INAHGQLVIA
N 12- NAHGQLVIA
N 13- AHGQL VIA
N 12- NAHGQLVI
100
B. Donor A 1-
vac- N
vac
N 416-429 VKVKEISNQEPLKL
N 416-428 VKVKEISNQEPLK
N 416-427 VKVKEISNQEPL
N 418-429 VKEISNQEPLKL
N 420-429 EISNQEPLKL
N 422-429 SNQEPLKL
N 421-429 ISNQEPLKL
100
C. Donor C 3A-
vac- N
vac
N 7-21 LQREINAHGQLVIA
N 7-20 LQREINAHGQLVI
N 7- 19 LQREINAHGQLV
N 9- REINAHGQL VIA
N 11- INAHGQL VIA
N 12- NAHGQLVIA
N 13- AHGQL VIA
N 12- NAHGQL VI
100
D. Donor C 3A-CI0
vac-
vac
N 416-429 VKVKEISNQEPLKL
N 416-428 VKVKEISNQEPLK
N 416-427 VKVKEISNQEPL
N 418-429 VKEISNQEPLKL
N 420-429 EISNQEPLKL
N 422-429 SNQEPLKL
N 421-429 ISNQEPLKL
100
% Specific Lysis
Figure 111-2: Localization of CTL epitopes on HTNV N protein recognized by representative
CTL lines from donors A and C. Target cells were autologous BLCLs either infected with
vac-N or wild-type vac or pulsed with peptide (25 J.g/ml). EfT = 10: 
A. N12-
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Figure 111-3: Peptide dose-response curves for N peptide-specific CTL lines from Donors A
and C. Autologous BLCLs were pulsed with peptide at the indicated concentrations. (A)
CTL lines specific for N12_2o. (B) CTL lines specific for N42I 429. Data from a representative
experiment is shown. EfT = 10: 1.
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C. HLA Restriction of N-specific CDS+ CTL lines.
HLA restriction of the CDS+ CTL lines was determned by testing each CTL line
against a panel of partially HLA-matched allogeneic BLCL infected with a vaccinia
recombinant expressing the HTNV N protein. To ensure that lysis of the allogeneic targets
was not due to recognition of an allogeneic or vaccinia determnant , each target cell line was
also infected with WT vaccinia virus and tested in the same assay. The results of the HLA
restriction analysis of representative CTL lines isolated from donors A and C are shown in
Figure III-
All of the CDS+ CTL lines generated from donor A recognized and lysed allogeneic
target cells expressing both HLA Al and B51 (Figure III-4A&B and data not shown). CTL
lines 3-G7 and 1O-E2, which recognized N12-2o, also recognized an Hmy-2CIR cell line
expressing only HLA B51 , indicating that these CTL lines are restricted by HLA B51 (Figure
III-4A and data not shown). CTL line l-CS, which recognized N 2I-429, did not recognize the
Hmy-B51 target cells. Since this cell line also recognized target cells expressing Al alone , it
must be restricted by HLA Al (Figure III-4B).
Donor C CTL line 3A- , which is specific for N12-2o, recognized only target cells
that express B51 , including the Hmy-2CIR-B51 cell line (Figure III-4C), which definitively
demonstrates that CTL line 3A-G3 is restricted by B51. CTL lines lA-B7, 3A- , 3A-
and 3A-CIO from donor C, which are all specific for N42I -429, recognized allogeneic target
cells expressing both Al and All , Al and BS and Al and B51 (Figure III-4D and data not
shown) but did recognize other targets expressing All , BS or B51 , indicating that these cell
lines are all restricted by HLA AI.
The B51-restricted epitope N12-2o (NAHEGQLVI) conforms to the consensus HLA
B51 binding motif with an Ala at position 2 (A, P or G preferred) and an He at position 9 (lor
V preferred). The AI-binding peptide N42I 429 (ISNQEPLKL) conforms poorly to the HLA
Al binding motif, which contains a glutamine or glutamic acid at position 3 and an aromatic
tyrosine at position 9 (189).
In summary, CTL lines from both donors that recognized the N-termnal nucleocapsid
epitope (N 20) were restricted by HLA B51 while CTL lines that recognized the C-termnal
nucleocapsid epitope (N 2I-429) were restricted by HLA AI.
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Figure 111-4: HLA restriction of CTL lines from donors A and C. CTL lines were tested in
Cr-release assays against a panel of parially HLA-matched allogeneic target cells infected
with vac-N. The HLA alleles shared by the donor (autologous) and the allogeneic target cells
are shown on the y axis. Data from representative experiments are shown. EfT = 10: 1.
D. Cross-reactivity of CTL lines isolated from HTNV - immune donors
Little is known about cross-reactive immunity between different hantaviruses. The
hantavirus N proteins have an overall sequence identity of 50% , although specific regions of
the protein are more highly conserved (e.g. the C-termnall00 amno acids are 85%
identical). Closely related hantaviruses , such as HTNV and SEOV , have nucleocapsid
proteins that are 82% identical. The high level of sequence identity suggests that hantavirus
infection may result in the development of immune responses that are cross-reactive among
numerous hantaviruses. To test whether the CTL lines were cross-reactive with other
hantaviruses , we tested the CTL lines for recognition of target cells infected with a
recombinant vaccinia virus expressing the SNV N protein. The CTL lines were also tested
against targets pulsed with corresponding 9-mer peptide epitopes from various other
hantaviruses , which were synthesized based on published sequences.
The CD8+ CTL lines that recognized the N-termnal epitope N12-2o (donor A:3- , 10-
E2; donor C:3A-G3) did not recognize target cells infected with a recombinant vaccinia virus
expressing the SNV N protein or target cells pulsed with 9-mer peptides representing the
corresponding epitope from varous other hantaviruses including SNV , DOBV , PHV , ANDV
and PUUV (Figure IIl-5& IIl-6A). This epitope is varable among the different hantaviruses
differing by up to 4 amno acids (Figure 6A). The DOBV peptide vares by only one amno
acid (A2--N) from the HTNV epitope , but was not recognized by any of the CTL lines
(Figure llI-6). This lack of recognition may be the result of the loss of peptide binding to the
HLA B51 molecule , since the amino acid change in the epitope derived from DOBV occurs at
an anchor position. However, we have not performed peptide binding studies to formally
demonstrate this. The SEOV peptide also varies by only one amino acid from the HTNV
epitope (NI-7S); it was recognized by CTL lines 3-G7 and 3A-G3 but not by 1O-E2 (Figure
III-6A).
The CTL lines specific for the C-termnal epitope N42I 429 (Donor A: l- , Donor C:
lA- , 3A- , 3A-C4 and 3A-ClO) all recognized target cells infected with a vaccinia
recombinant expressing the SNV N protein (Figure III-5). It is not surprising that these CTL
lines are cross-reactive with the SNV nucleocapsid since the epitope is identical between the
two viruses (ISNQEPLKL). This result demonstrated that the epitope is processed and
presented in the context of infection with a recombinant vaccinia virus expressing either
HTNV or SNV N. This epitope is also identical in other hantaviruses including ANDV
NYV , DOBV and SNV strain CCI07. The corresponding C-termnal epitope in PUU
PHV , and Bayou virus (BA YV) differs by one amino acid with a conservative Leu to He
change at position 9. Four of the five CTL lines isolated recognized this epitope: Donor A: 1-
CS and Donor C: lA- , 3A- , 3A-ClO (Figure III-6B and data not shown). The epitope in
SEOV also differs from the HTNV epitope by one amino acid with a Leu to Met change at
position 7. Three of the five CTL lines lysed target cells pulsed with this peptide; cell lines
lA-B7 and 3A-C4 failed to recognize and lyse these target cells (Figure II-6B and data not
shown). The differences between the CTL lines in recognition of the peptides derived from
the varous hantaviruses indicate that these CTL lines are heterogeneous and are not likely to
have resulted from the monoclonal expansion of a single dominant clone.
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Figure 111-5: Recognition of SNV or HTNV N protein by HTNV -specific CD8+ CTL lines
from Donors A and C. Autologous BLCLs were infected with recombinant vaccinia viruses
expressing either HTNV N or SNV N. BLCLs infected with wild-type vaccinia virus were
used as a negative control. EfT = 10: 
A. N 12-
HTN 12-20 NAHEGQL VI
SEO 12-20 .sAHEGQL VI
DOB 12- 20 GQLVI
12- 20 TRHEQQLVI
AND 12-20 T AHEQQL VI
PUU 12-20 TRHEQQLV
SNV 12-20 HEQQLVI
B. 421-429
HTN 421-429 ISNQEPLKL
PUU 421-429 ISNQEPLKI
SEO 421-429 ISNQEP
o 3A-G3 (Donor C)
1O-E2 (Donor A)
.3-G7 (Donor A)
100
o 3A-C4 (Donor C)
3I3A-B8 (Donor C)
. lA-B7 (Donor C)
100
Figure 111- 6: Cross-reactivity of representative CD8+ CTL lines from Donors A and C
against corresponding epitopes from several hantavirus N proteins. CTL lines were tested
against autologous BLCLs pulsed with the indicated epitopes at 25 Ilglml. Amino acids that
differ from the corresponding amino acid in the HTNV peptide are underlined. EfT ratio =
10: 1. (A) CTL lines specific for N 12-20. (B) CTL lines specific for N 21-429.
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E. Recognition of HTNV N epitopes in 7-day bulk culture
The HTNV -specific clones isolated from donors A and C are all specific for one of
two epitopes on the nucleocapsid protein. Both epitopes are located at the termni of the
protein , potentially allowing them to be more rapidly degraded and more efficiently presented
on MHC class I molecules than more internally located peptides. In order to address the 
vivo significance of these epitopes in Donor C , we tested recognition of these epitopes in bulk
cultures after short-term stimulation with inactivated HTNV. Seven day bulk cultures of
donor C PBMC demonstrated significant recognition of both peptide epitopes, with the N-
terminal epitope (N 12-20) being recognized at levels comparable to that of the whole N protein
(vac-N) (Figure III-7). Frequency analysis confirms that T cells recognizing these two
epitopes are present at relatively high frequencies in the peripheral T cell pool. Single cell
IFN-y secretion analysis (ELlS POT) of donor C PBMC indicates that T cells specific for N12-
20 have a frequency ranging from 1/7 ,326- 1/8 968 PBMC , and T cells specific for N421 429
have a frequency ranging from 1/18, 181- 1/19 417 PBMC. These frequencies are comparable
to those detected for several immunodominant epitopes from influenza virus (187 , 190).
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Figure 111-7: Recognition of HTNV proteins and identified CTL epitopes following short-
term in vitro stimulation. PBMC (2-5 X 106) were stimulated with y-irradiated HTNV for 7
days. The bulk culture was tested on day 7 against autologous BLCLs either infected with
recombinant vaccinia viruses expressing HTNV proteins or pulsed with the indicated peptides
(25 glml). EfT ratio = SO: 1.
CHAPTER IV
HIGH LEVELS OF HUMAN MEMORY CTL FOLLOWING CLINICAL PUU
INFECTION: DOMINANT AND POL YCLONAL CTL RESPONSES TO THE
NUCLEOCAPSID PROTEIN
Initial studies of memory T lymphocyte responses in individuals who had subclinical
laboratory-acquired infections with HTNV provided the first demonstration of CTL responses
to viral proteins and description of CTL epitopes on the virus. We were also interested in
studying memory T cell responses in individuals who had HFS as a result of natural
exposure to the virus. To study memory T cell responses following the resolution of HFS
acquired naturally, we studied a group of 13 Finnish individuals who had clinical infections
with PUUV between the years 1984 and 1995 (Table IV- I). These subjects were all
hospitalized with HFS , but had varying degrees of disease severity.
The goals of this study were as follows: I.)Identify the viral proteins targeted by the
CTL response following PUU infection; 2. ) Identify and characterize CTL epitopes on
PUU; 3.) Assess whether the CTL responses detected in these individuals were cross-
reactive with other hantaviruses; and 4.) Quantitate the PUU epitope-specific CTL precursor
frequencies in all the donors.
A. Dominance of PUUV N protein as target of memory CTL during HFRS
PBMC from eleven donors who had HFS between the years 1984 and 1995 were
stimulated in vitro for 7 to 8 days with live PUUV. Following in vitro stimulation , bulk
cultures were screened for recognition of autologous BLCLs infected with recombinant
vaccinia viruses expressing PUU proteins. CTL responses against one or more PUU
proteins were detectable in PBMC from 7/11 donors. CTL activity was directed against the N
protein in 6 of the cultures (donors 1-6), against the Gl glycoprotein in 5 (donors 1 6 &
7), and against the G2 glycoprotein in 2 (donors 3 & 6) of the cultures (Figure IV- I).
Following re-stimulation with PUU and autologous, irradiated PBMC , we were able to
detect CTL responses against N protein in bulk cultures from two of the donors in which
virus-specific responses were undetectable at day 7-8 (data not shown). High levels of
vaccinia virus (vac)-specific "background" CTL responses were detected in the bulk cultures
from three donors (donors 4 5 & 7), despite the inclusion of unlabeled vac-infected target
cells in the assays. The specific lysis of wild-type (WT) vaccinia virus-infected targets in
these cultures was 26% , 18% and 29%, respectively. However, the lysis of target cells
infected with recombinant viruses expressing PUU proteins was significantly higher than
that of target cells infected with wild-type vaccinia virus. Vac-specific responses in all other
donors were less than 5%. The specific lysis of target cells infected with vaccinia virus
recombinants expressing PUU proteins was considered to be positive if it was greater than
10% above that of WT vaccinia virus-infected targets.
PUU -specific CTL cell lines were identified and characterized by in vitro expansion
and cloning of bulk cultures from donors 1 and 2. Forty-three PUU -specific cell lines were
isolated from donor 1; of these 42 were N-specific and 1 was Gl-specific. Twenty cell lines
were isolated from donor 2; of these 19 were N-specific and 1 was G2-specific. The
predominance of cell lines specific for N suggests that the N protein may be the dominant
target of the T cell response during PUUV infections. The fact that we were only able to
identify one G I-specific cell lines from donor 1 was somewhat surprising, since the bulk
culture from this donor showed comparable levels of N- and Gl-specific CTL activity. We
did not detect bulk culture CTL specific for G2 in either of these donors. However, the fact
that G2-specific CTL responses were detected in bulk cultures from two other donors (Figure
IV- I), and the recovery of a G2-specific CTL line from donor 2 , indicates that these cells
were present at detectable levels in some individuals.
Table IV-I. Characteristics ofPUUV-immune donors.
Current HLA Class I Alleles
Donor # Age (yrs ) Year of Ilness
1986
1994
1994
1990
1990
1995
1988
1985
1987
1991
1988
1988
1984
DGI
G2/Bs
II Gs/Sm
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Figure IV-I: Bulk culture recognition of PUU proteins. PBMC (4-5XI0 ) were stimulated
with 20 J!l of infectious PUUV (strain K27) and cytotoxicity assays were performed using
autologous BLCLs infected with recombinant vaccinia viruses expressing PUU N , Gl
G2/Bs or G2/Sm protein as targets. The recombinant vaccinia virus designated vac-G2/Bs
contains the first half of the G2 cDNA , encoding amino acids 1 to 256 , and the recombinant
designated vac-G2/Sm contains the second half of the G2 protein , encoding amno acids 227
to the end of the protein. EfT ratios were 60: 1 or 80: 1. Unlabeled wild-type vaccinia virus
infected BLCL were included in all wells at a ratio of 10: 1 unlabeled: labeled targets, to
reduce levels of vac-specific lysis. Data shown represent the percent specific lysis after
subtraction of wild-type vaccinia virus background lysis. Responses greater than 10% above
background were considered positive.
B. Broad CTL responses to PUUV N protein in two individuals
Nucleocapsid-specific CTL isolated from donors 1 and 2 were characterized using a
panel of overlapping 15-mer peptides that span the PUUV N sequence. Each CTL line
isolated recognized target cells pulsed with only one or two (adjacent) of the 70 overlapping
peptides that span the N protein (data not shown). Optimal CTL epitopes were then defined
by testing each CTL line against sequential N- and C-terminal truncations of the
appropriate 15-mer peptide. The restricting HLA alleles required for peptide recognition by
these CTL lines was determned using a panel of partially HLA-matched BLCLs as targets in
Cr-release assays (data not shown). A summary of the epitopes and representative CTL
lines identified in these donors is shown in Table IV -
CD8+ CTL lines from donor 1 were found to recognize one of four epitopes: 1
restricted by A2 (N204 d, 1 restricted by B7 (N173-81) and 2 restricted by B8 (N17-81 and N243-
5d. CD4+ CTL lines were also isolated from this donor which recognized N239 5o. The
restricting allele for these CD4+ CTL lines has yet to be determined. Figure IV-
demonstrates the cytolytic activity of the CD8+ CTL lines using target cells pulsed with
increasing dilutions of the optimal peptide epitopes.
The CTL clones specific for N 04-12 appeared to have a range of affinities for the
peptide/MC complex , as reflected by the wide range of peptide concentrations required for
sensitization of target cells (Figure IV -3A). This peptide (GLFPTQIQV) conforms to the
defined HLA binding motif for A2 , with the preferred leucine at position 2 and valine at
position 9.
The CTL lines specific for N173 81 displayed more uniform peptide dose-response
curves, suggesting that their TCRs have similar affinities for the peptide-MHC complex
(Figure IV-3B). It is interesting to note , however, that we identified both B7-restricted (3-
and 10-F5) and B8-restricted (1O-G4) CTL lines that recognized the same epitope (Table IV-
and Figure IV-2). This peptide (RPKH YVSM) conforms to the defined HLA B7 motif
reasonably well , with the preferred proline at position 2 and a methionine at position 9 (L or F
preferred); and to the BS motif less well , with the preferred lysine at position 3 but a leucine
at position 5 (K or R preferred).
CD8+ CTL from donor 2 were also found to recognize one of four epitopes: 1
restricted by HLA A2 (N204 12), 1 restricted by A28 (N 164-78) and 2 (N236 50 and 212 20) for
which the HLA restriction has yet to be determned. CTL lines specific for the latter two
epitopes were tested against a large panel of partially HLA-matched target cells , including
cells matched at each of the HLA A and B alleles (Table IV-I). CTL lines specific for these
epitopes recognized only a single allogeneic target cell line that shares A2, A28 and B44.
However, these CTL lines failed to recognize numerous other target cell lines sharng these
alleles , as well as those sharng HLA BS (data not shown). The data suggest that the
restricting allele used by these CTL lines is likely to be an HLA Cw allele.
The cytolytic activity of CTL lines specific for N 50, N212 20 and N 164-78 is shown in
Figure IV -4. The CTL lines specific for N236 50 required very high peptide concentrations for
sensitization of target cells (Figure IV -4A). The length of this peptide (15 amino acids) is
probably sub-optimal for binding to the class I HLA molecule and this may account for the
absence of target cell recognition at lower peptide concentrations. However, single amno
acid deletions from either the N- or C-termnal end of this peptide abolished recognition by
these CTL lines , suggesting that the entire 15-mer is required for recognition (data not
shown).
The two CTL lines specific for N212-20 appeared to have comparable affinities for the
peptide/MC complex , as reflected by the similar peptide dose-response curves (Figure IV-
4B). The CTL line 3-B8 was tested against a 15-mer peptide (N164 78) and required lower
peptide concentrations for target cell sensitization than required by the CTL lines specific for
N 236-50.
Table IV -2. Summary of Characterized CTL Lines Specific for PUUV N Epitopes.Donor CDS/CD4 HLA Restriction Amino Acids CTL LinesCDS A2 204-212 lA-CII
lA-DIO
lA-
IB-
DIO
El1
10- B 10
CDS 173- 181
1O-
CD4
173- 1S1
243-251
239-250
IO-CDS
CDS lA-
BIO
CD8 204-212
CDS A28 164- 17S
CDS 212-220
IB-
CDS 236-250 lA-Dll
IB-
10- B4
1O-
Hmy-
Autologous
. 10-
E1 1O-
m 3-
Hmy-
Hmy-
Hmy control
% Specific Lysis
Figure IV -2: HLA restriction of N 173-81 -specific CTL lines isolated from donor 1.
Autologous BLCL or Hmy.CIR cell lines expressing the indicated HLA allele were infected
with a recombinant vaccinia virus expressing PUU N and used as targets in a Cr-release
cytotoxicity assay. E/T=IO.
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Figure IV -3. Peptide dose-response curves of CDS+ N -specific CTL lines isolated from
donor 1. A) CTL lines specific for the A2 epitope N204 12. B) CTL lines specific for the
B7,BS epitope N17-81. C) CTL line specific for the BS epitope N 43-51. Lysis of targets not
pulsed with peptide was negative in all assays.
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Figure IV -4. Peptide dose-response curves for CD8+ N-specific CTL lines isolated from
donor 2. A) CTL lines specific for N236 so. B) CTL lines specific for N212 20. C) CTL line 3-
, specific for the A28-restricted epitope N 164-78.
C. High frequencies of PUU-specific CTL in PUUV-immune individuals
In order to determne whether the epitopes identified in this study are determnants
that are commonly targeted by PUUV-specific CTL, we studied a panel of PBMC from 13
PUU -immune donors , including the 7 donor PBMC in which PUUV -specific responses
were detected in bulk cultures (Figure IV- I). Each of the 13 individuals expresses one or
more of the restricting HLA alleles required by the CTL clones isolated from donors 1 and 2
(Table IV- I).
Of the 13 individuals tested, 8 had detectable PUUV-specific T cell responses in 16-
hour IF-y ELISPOT assays (Figure IV-5). Three individuals had high frequencies of
epitope-specific T cells in their PBMC (donors 1 , 11 & 13; Figure IV -5A), with some epitope-
specific T cells present at frequencies as high as 300 per 10 PBMC. The hierarchy of epitope
recognition vared from donor to donor, with different epitope-specific responses dominating
in different individuals. The N17-81 response dominated in donor 1 , the N243 51 response in
donor 11 , and the N 04-12response dominated in donor 13.
Five additional donors (donors 2 , 6 , 7 , 9 & 10) had somewhat lower responses to these
epitopes (Figure IV-5B). The frequency of epitope-specific T cells seen in these donors was
between 13 and 61/10 PBMC. These responses are comparable to frequencies of many
commonly recognized influenza virus epitopes (187 , 190). In fact , when PBMC from the 3
A2+ donors in this study were stimulated with the influenza A epitope M158- in ELlS POT
assays , none of the donors had detectable responses (Table IV -3). In these donors , the
hierarchy of responses also vared between individuals.
A summary of the range of precursor frequencies seen in these donors is shown in
Table IV -3. Of the three epitopes to which T cell responses were detected, the A2-restricted
epitope (N204 d was recognized most consistently, with detectable responses seen in all A2+
donors tested (3/3). The BS-restricted epitope N243 51 was recognized in 8 of 12 donors tested
and the N17-81 (B7 or B8 restricted) epitope was recognized in 2 of 12 donors. We did not
detect IFN-y responses to the N164 78 epitope in any of the A2S+ donors tested (3/3), including
the donor from whom the N 64-78-specific clone was isolated (donor 2). Since we have not
identified the optimal epitope recognized by this CTL, we used a 15-mer peptide to stimulate
the PBMC in the ELlS POT assays. It is possible that this peptide is not optimal for
stimulation of epitope-specific cells and this may have contributed to our inability to detect a
response in the donors expressing A2S. It is also possible that the frequencies of T cells
specific for this epitope were below the limit of detection.
These data demonstrate that PUU N -specific memory CTL are abundant in the
peripheral blood of immune individuals for many years after acute infection, and that
detection of these memory CTL populations does not require in vitro expansion.
We did not detect responses to any of the 4 defined CD8+ epitopes in the PBMC of the
other 5 donors (donors 3 , 4 , S & 12). It is clear that virus-specific memory T cells are
present in the PBMC of these donors , since N-specific CTL activity was detectable in at least
3 of these donors ' PBMC (donors 3 , 4 & 5) following 7 days of in vitro stimulation with
infectious PUU (Figure IV- I). It is likely that there are other CDS+ epitopes on the N
protein that have not yet been identified, and that CTL with distinct specificities contribute to
the CTL response in these donors. We have also demonstrated proliferation responses to
inactivated PUU in these donors (data not shown), further indicating that all donors possess
virus-specific memory T cells.
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Figure IV -5. Detection of virus-specific CD8+ memory T cells by IFN-y ELISPOT. PBMC
were stimulated with 10 glml of the indicated peptides in a 16-18 hour assay. Input cell
numbers ranged from 2-4xI0 / well. Peptide stimulations were performed in triplicate wells.
PBMC stimulated with a B8-restricted epitope from Hepatitis C virus NS3 (NS31402-1411) were
included for comparson with PUU -specific BS-restricted epitopes. PBMC incubated with
medium alone were included as negative controls. The data are presented as # of IF-
producing cells/10 PBMC , with medium control values subtracted. The number of spots in
the medium control wells ranged from 0 to 5. All ELISPOT experiments were performed at
least twice and mean values are shown. A) PUUV -immune individuals who had high
precursor frequencies (::100/1 0 PBMC) of CTL specific for one or more CD8+ epitopes on
PUU N. B) PUU-immune individuals who had lower precursor frequencies (10-100/10
PBMC) of CTL specific for one or more CD8+ epitopes on PUU 
Table IV - Recognition of CDS+ PUUV epitopes in PBMC from immune donors.
HLA #of #of Range of IF-y producing
Epitope restriction donors tested* responders T cells/10 PBMC
N 173- 52-304
243 13- 188
204 16- 200
164 A28
731 A24
Flu M158-
*Only donors possessing the indicated HLA allele were tested.
D. Cross-reactivity of CTL lines isolated from donors 1 and 2
We were interested in learning whether the CTL responses generated against one
hantavirus also recognized the corresponding epitopes from other hantaviruses , thus
potentially conferrng cross-protective immunity. We therefore tested the CTL lines isolated
from donors 1 and 2 against autologous BLCLs infected with recombinant vaccinia viruses
that express either PUUV , HTNV or SNV N proteins. As shown in Table IV- , the CTL lines
specific for N202 12 failed to recognize the N protein from either HTNV or SNV. The
sequences of HTNV and SNV N proteins both differ from the PUUV sequence at this epitope
by 4 amino acids, including a V to A change at the anchor position 9 (Table IV -5). Of the
two B7-restricted and one B8-restricted CTL lines that recognized PUU N173-81, only IO-
displayed cross-reactive recognition of the HTNV N protein. This epitope is fairly well
conserved among the viruses; both the HTNV and SNV sequences at this epitope differ from
the PUUV epitope by only two amino acids , and in both the preferred P at position 2 is
conserved (Table IV -5).
The CD8+ CTL lines from donor 2 that recognize PUU N so are also primarly
PUU -specific with most displaying no recognition of targets expressing either the HTNV or
SNV N protein. However one CTL line, IB-G9, consistently recognized targets expressing
the SNV N protein as well as those expressing the PUU N protein (Table IV -4). The
sequence at this epitope is extremely varable among different hantaviruses (Table IV -5), and
it is thus surprising that this CTL line was able to recognize the corresponding sequence from
the SNV N protein.
Neither of the cell lines that recognize PUU N212-20 were cross-reactive with HTNV
or SNV N protein , despite the relatively high level of sequence conservation at this epitope
(Table IV -5). However, since we have not yet determned the HLA restriction of these CTL
lines , we cannot accurately predict which residues within the epitope might be critical for
recognition of the peptide-HLA complex by the TCR , or for binding of this peptide to the
HLA molecule. Finally, the CTL line that recognizes N164 78 (3-BS) is cross-reactive with the
HTNV N protein , but does not recognize the SNV N protein. This epitope is relatively well
conserved between PUUV and HTNV virus , with the corresponding epitope on HTNV N
differing by 3 amino acids , and less well conserved between PUU and SNV viruses , which
differ by 6 amino acids at this epitope.
In summary, of 22 CTL lines tested for cross-reactivity against HTNV and SNV
viruses only 3 CTL lines showed cross-reactive lysis, suggesting that the CTL responses
identified in this study were highly PUUV-specific. None of these cross-reactive CTL lines
recognized the N protein from both HTNV and SNV viruses , despite the fact that some of the
epitopes share considerable sequence identity among the different hantaviruses.
Table IV-4. Cross-reactivity of PUUV N-specific CDS+ CTL lines.
% Specific Lysis
Donor CTL Line Epitope PUU N HTNV N SNVN
lA-CII N204- 44. 1.1 1.1
lA-DI0 N204- 41.5 1.2 3.3
lA- N204- 49.
IB- N204- 50. 1.7 1.4
N204- 36.4
D 10 N204- 56.
N204- 41.4
Ell N204- 43.4
10-B 10 N204- 37.
N173- 18.
10- N173- 33. 25.
10- N173- 22.4 1.8
lA-Dl1 N236- 19. 1.0
IB- N236- 20. 1.8 22.
N236- 19.
N236- 24.
1O- N236- 18.
1O- N236- 17.
lO-Ell N236- 20. 1.7
N212- 27. 1.7
N212- 27. 0.4 1.9
N164- 27.4 25.
*E/T ratio = 10.
Specific lysis values ::10% above background were considered positive and are underlined.
Table IV-S: Sequence comparison of epitopes between PUUV Hf and SNV viruses.
N204- PUUV G L F P T Q I Q V
HTNV G L Y P A Q I K A
SNV G L F P A Q V K A
N173- PUUV R P K H L Y V S M
HTNV K P K H L Y V S
SNV K P R H L Y V S
N243- PUUV E C P E V
HTNV P C K L P D T A
SNV R C F L P E Q K
N236- PUUV R E F M E K E C K P E
HTNV E Q W E P C K L P
SNV D D L A C P L P E Q
N212- PUUV V R N M S P V M
HTNV A R Q P V M
SNV A R N P V M
N164- PUUV T S E 0 N G R R P K H
HTNV S S E 0 V N G R K P K H
SNV S S Y E E V N G R K P R H
E. Heterogeneity of CDS+ CTL clones specific for N204
Since we identified numerous CTL lines from donor 1 that were specific for the same
peptidelHA combination , we were interested in determning whether this population was
polyclonal. To assess the diversity of the N204-12-specific T cell clones isolated from donor 1
we identified the TCR VB chains expressed by these clones using PCR amplification. 
single PCR product was generated for each clone , indicating the expression of a single TCR
VB chain (data not shown). A summary of the TCR VB chains expressed by 9 CTL clones
specific for N204 12 is shown in Table IV -
Among the 9 CTL clones analyzed, we found 5 different VB chains that were
expressed, including Vj3 2 , 3 , 5.2 , 8 and 13. 1. Three of the CTL clones expressed Vj313.
and three expressed VB5.2 , suggesting that these Vj3 chains may be preferentially used by
CTL specific for this epitope. Further phenotypic analysis , including Va chain usage and
CDR3 sequencing, wil be required to determne if the clones that express the same VB chains
are distinct from one another, or if they represent the progeny of a single precursor clone. The
fact that 5 different TCR VB chains were used by 9 CTL clones suggests that the TCRs
expressed by this CTL population are quite diverse and that multiple TCR rearangement
events occurred to produce CTL clones that recognize the identical peptide.
Table IV -6: Summary of TCR VB chains expressed by NZ04 IZ-specific T cell clones
isolated from donor 1.
Clone TCR V
lA-CII 13.
lA- 13.
lA-DIO
lA-
IB-
DI0 13.
10- B 10
F. Isolation and characterization of a PUUV G2-specific CDS+ CTL clone
In addition to isolating numerous virus-specific CTL lines that were specific for the
PUUV N protein , we were able to isolate and characterize one CTL clone that was specific for
the PUUV G2 glycoprotein from donor 3. This CTL clone was derived from a bulk culture of
PBMC that had been stimulated with inactive (y-irradiated) PUU K27 virus (kindly provided
by Connie S. Schmaljohn), and was the only CTL line that was successfully isolated and
maintained from this culture.
This clone was later shown to reproducibly recognize targets infected with the vac-
PUU G2/Bs and vac-SNV G2 recombinants (Figure IV -6 & data not shown). In fact, the
recognition of target cells infected with vac-SNV G2 was consistently higher than that of
target cells infected with vac-PUU G2/Bs (Figure IV-6). This is likely to be due to the
relatively low level of G2 protein expression from the recombinant vaccinia virus expressing
the PUUV G2 protein (Terajima, Van Epps et ai , manuscript in preparation). Since the
recognition of the vac-SNV G2 construct was superior to that of the vac-PUU G2/Bs
construct, we used this recombinant virus , as well as overlapping peptides derived from SNV
, to further characterize the clone.
HLA restriction of clone lA-E2 was determned by screening a panel of parially
HLA-matched allogeneic BLCL infected with vac-SNV G2 as target cells in cytotoxicity
assays. These experiments clearly demonstrated that the clone was restricted by HLA A24
since this was the only HLA allele that was shared by all the target cells recognized by the
clone (Figure IV -7).
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Figure IV -6: Recognition of hantavirus G2 glycoproteins from PUU , SNV and HTNV
viruses by CTL clone lA-E2 from donor 3. The clone was tested in Cr-release cytotoxicity
assays for recognition of autologous BLCLs infected with vaccinia virus recombinants
expressing PUU G2/Bs, SNV G2 or HTNV G2. E/T=IO.
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Figure IV-7: HLA restriction of CTL clone lA-E2 from donor 3. The clone was tested in
Cr-release cytotoxicity assays against a panel of parially HLA-matched allogeneic target
cells infected with vac-SNV G2. The HLA alleles shared by donor 3 (autologous) and the
allogeneic target cells are shown on the y axis. Err=lO.
To identify the precise epitope within the G2 protein that was recognized, we tested
the clone in cytotoxicity assays against a panel of overlapping 20-mer peptides spanning the
first half of the SNV G2 protein (data not shown). This analysis revealed that a single 20-mer
peptide which spanned amino acids 747-766 (HAEIQNLGHWMDGTFNIKTA) on the SNV
M segment was capable of sensitizing target cells for lysis by the lA-E2 clone. The sequence
of this region differed between SNV and PUU G2 proteins by 3 amno acids (PUU M723-
742: HAEIQHLGHWMDA TF'KT A). Sequential C- and N-termnal truncations of the
PUU M723_742 peptide showed that the minimal peptide required for sensitization of target
cells for lysis by the lA-E2 clone was a 9-mer peptide spanning amino acids 731-739 (Figure
IV -S). Target cells pulsed with peptides M727-38 and M725-36 were recognized and lysed, but
levels of lysis of these targets was considerably lower than those pulsed with the M731-
peptide. Target cells were sensitized for lysis by the clone with peptide concentrations as low
as 25 nM of peptide M731-39 (Figure IV -9).
HWMDATFN PUU M731-
HWMDA TFNLKT A PUU M731-
LGHWMDATFNLK PUU M729-
QHLGHWMDATFN puu M727-
EIQHLGHWMDAT PUU M725-
HAEIQNLGHWMDGTFNIKT A SNV M747-
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Figure IV -8: Localization of the minimal peptide epitope on PUU G2 protein recognized
by clone lA-E2 from donor 3. Target cells were autologous BLCLs pulsed with the indicated
peptides (25 J.M). E/T=lO.
...
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Peptide Concentration (uM)
Figure IV -9: Peptide dose-response curve for PUUV G2-specific CD8+ CTL clone lA-E2.
Autologous BLCLs were pulsed with the indicated concentrations of peptide PUU M731-
and were used as targets in Cr-release cytotoxicity assays. E/T=lO.
G. Comparison of levels of virus-specific T cell memory with disease severity
An eventual goal of our research is to correlate levels of virus-specific T cell
activation with the severity of hantavirus disease. This comparson should provide some
insight into the role of T cells in the immunopathology of and/or recovery from hantavirus
infection. To evaluate whether there was a correlation between levels of virus-specific T cell
memory and severity of the acute ilness , we compared total virus-specific memory CDS+ T
cell responses (total of precursor frequencies for all epitopes recognized) with varous clinical
parameters recorded during the acute ilness. The clinical characteristics of the donors are
shown in Table IV - , and the total virus-specific memory T cell responses are shown in Table
IV -S. Regression analysis demonstrated no statistically significant correlations between the
total virus-specific memory T cell response and any clinical measurement, including peak
serum creatinine levels, peak urine protein levels , peak hematocrit levels, nadir platelet count
maximum polyuria, blood pressure , duration of fever, length of hospital stay or requirement
for dialysis.
We observed weak trends suggesting that the overall level of virus-specific T cell
memory may be correlated with maximum urine protein levels, maximum levels of C-reactive
protein and duration of fever (Figure IV- lO). However, our sample size was extremely small
and many more subjects would be needed to identify statistical correlations. Furthermore
since we are only including memory CTL that recognize a maximum of three epitopes (N17-
81, N204 12, N243 51) in our calculation of total virus-specific memory T cell responses , it is
possible that these totals are not representative of the overall levels of PUUV 
-specific T cell
memory in these individuals. This analysis also excludes individuals who do not express the
restricting HLA alleles identified in this study.
Table IV-7: Clinical characteristics ofPUU-immune donors during HFRS
Donor Year of Max. Max. Min. Max C-react.HFS creae urine prot. platelets prot.1986 194 2230 114 1994 987 980 178 1994 207 790 39 1011990 237 3240 52 1990 466 ND 150 1995 1156 ND 19 1988 841 540 59 1985 238 2120 58 1987 515 430 10 10 1991 293 700 11 1988 361 2180 95 12 1988 1011 ND 10 10913 1984 929 440 47 
Highest serum creatinine during hospital care (/-M)
Highest daily urine protein level (mglday)
Lowest platelet count observed (xI0 /L)
Highest C-reactive protein observed (mgI)
Table IV-7(cont): Clinical characteristics ofPUU-immune donors during HFRS
Donor Year of Max. Max. Duration Length of
HFRS hematocr.e polyuria. of feve time in hosp. Dialysis1986 0.45 2550 
1994 0.36 4700 1994 0.43 3400 14 1990 0.47 3150 1990 0.42 5950 11 
1995 0.56 3356 
1988 0.63 2860 1985 0.41 5700 
1987 0.54 3250 10 1991 0.61 3500 11 1988 0.41 2500 12 1988 0.62 6410 13 1984 0.35 8280 20 
Highest hematocrit measured during hospital care
Highest daily urine volume (ml/day)
gDuration of fever (days)
Length of hospital stay (days)
Table IV -8: Summary of frequencies of virus-specific memory CD8+ T lymphocytes in
PUUV -immune donors
HLA . fre . IFN- + T cellsll06 PBMC Total freq.
Donor N 173- 204 243 per 10 PBMC
304. 87. 444.4
ND* 49. 15. 65.
52. 61.4 113.
15. 15.
36. 36.
13. 13.
188 188
200. 92.4 292.
*Not detectable
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Figure IV- I0: Correlations of virus-specific memory T cell frequency and clinical
parameters of disease severity. Total frequencies of virus-specific memory CDS+ T cells were
calculated as the sum of average frequencies for 3 epitopes (N17-81, N 04-12, N243 51). Total T
cell frequencies were plotted against the following clinical parameters: A) Duration of fever
(days) B) Maximum urine protein (mg/day) C) Maximum C-reactive protein (mgI). R
values are shown. P values were 0. 174 (A), 0. 134 (B), and 0. 182 (C).
CHAPTER V
DISCUSSION
This thesis provides the first qualitative and quantitative analysis of the memory T cell
responses to hantaviruses that cause HFS. We have shown evidence for memory CTL
responses to hantaviruses in individuals following subclinical , laboratory-acquired infections
with HTNV and following clinical , naturally-acquired infections with PUUV. We have
demonstrated virus-specific CTL activity in bulk T cell cultures and have isolated and
characterized virus-specific T cell lines and clones. In the course of these studies , we
identified 8 CD8+ CTL epitopes (Table V- I) and one CD4+ CTL epitope on the N protein of
HTNV and PUUV as well as one CD8+ CTL epitope on the G2 protein of PUU. This is the
first demonstration of CTL responses to Old World hantaviruses in humans and the first
identification of CTL epitopes on these viruses.
We have also developed a quantitative RT-PCR assay to measure the viral RNA copy
number during acute PUU infections. This assay is similar to a quantitative RT -PCR assay
designed to measure SNV S segment RNA copy number in patient plasma that was developed
previously in our laboratory. This assay wil provide information on the quantity of virus
circulating in the blood during acute ilness , and wil allow us to identify potential correlations
between virus load and severity of ilness caused by PUU. The combined analysis of the
kinetics and magnitude of the viral load and of T cell responses during acute infection wil
provide insight into the mechanisms of disease pathogenesis.
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A. CD8+ CTL RESPONSES TO HTNV AND PUUV
Our aim in these studies was to analyze the specificity and diversity of bulk
culture and clonal CTL responses to the Old World hantaviruses HTNV and PUU.
1. CD8+ CTL responses following sub-clinical infections with HTNV
We first studied CTL responses in three donors who had laboratory-acquired
infections with HTNV 5- 15 years prior to this study. None of these donors became il , and
HTNV infections were confirmed by identification of HTNV -specific immunoglobulin in the
donors ' serum. Following in vitro stimulation of PBMC with inactivated virus , we detected
hantavirus-specific CTL responses in all 3 donors , indicating that sub-clinical infections with
HTNV induced virus-specific CTL responses. The bulk culture CTL response of each donor
was directed against a single viral protein: the HTNV N protein in donors A and C , and the
HTNV Gl protein in donor B (Figure il- I). The mechanism governing these differences in
protein recognition is not known , but may be due to differences in the number of potential
CTL epitopes in the proteins that are able to bind paricular HLA alleles for presentation to
virus-specific CTL.
Isolation of CTL lines from two donors (A & C) lead to the identification of two CD8+
CTL epitopes on the HTNV N protein. Both epitopes were located at the termni of the N
protein; one spanned amino acids 12-20 and the other amino acids 421-429 (Figure V- I and
Table V -2). The detection of CD8+ CTL responses in these cultures following stimulation
with inactivated virus indicated that the viral peptides were able to access the HLA class I
presentation pathway following endocytosis of the inactivated virus. The abilty of exogenous
antigens to prime the MHC class I presentation pathway, traditionally thought to present only
peptides derived from endogenously synthesized proteins , has been described in many
systems (191). In the early 1990s , two groups demonstrated that murine splenocytes exposed
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to exogenous chicken ovalbumin (OVA) in vitro were able to induce OVA-specific CD8+ T
cell responses either in vivo (192) or in vitro (193), ilustrating that the exogenous antigen was
able to access the MHC class I presentation pathway. Priming of CD8+ CTL by inactivated
viruses or soluble viral protein has also been demonstrated for other viruses including
influenza, Sendai , and Epstein Bar virus (EBV) (194- 196).
Attempts to isolate additional clones from both donors with different specificities were
unsuccessful. Additional CTL lines that were isolated all recognized the HTNV N12-20 or the
421 429 epitope. These data suggested that there were only a limited number of CD8+ CTL
epitopes on HTNV N proteins in these individuals. Alternatively, it is possible that the
method used to stimulate the PBMC , which presumably involved priming of the exogenous
class I pathway, led to the preferential activation and expansion of CTL specific for the
epitopes described. Both epitopes are located at the termnal ends of the protein , potentially
allowing them to be more readily degraded in endosomes and presented on MHC class I
molecules than more internal peptides. However, the mechanisms involved in CDS+ T cell
priming by inactivated HTNV were not directly investigated in these studies.
Additional CTL epitopes probably would have been identified if we had stimulated the
PBMC with infectious virus. Stimulation of PBMC with live virus would be more likely to
result in more efficient loading of antigenic virus epitopes into the classical HLA class I
pathway, and thus increase the likelihood of identifying virus-specific CD8+ CTL clones.
Schirmbeck et al demonstrated that some , but not all , MHC class I-epitopes are generated
during both endogenous and exogenous processing of the hepatitis B virus surface antigen
(HBsAg) (197). That study further demonstrated that there are some antigenic epitopes that
are only revealed during exogenous processing of viral proteins and subsequent presentation
via the class I pathway.
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Additional CD8+ T cell epitopes on HTNV may also be identified by screening virus-
stimulated bulk cultures against the entire panel of nucleocapsid peptides , or by stimulating
PBMC with individual or pooled peptides in ELISPOT assays. The potential of the latter
technique was demonstrated in a recent study in which PBMC from EBV+ donors were
stimulated with pools of overlapping peptides from the viral EBNAI protein (196). This
approach resulted in the identification of three novel CD8+ CTL epitopes on EBNAI. These
epitopes had not been identified previously because traditional approaches for detecting EBV-
specific CTL responses relied on stimulation of PBMC with EBV - transformed B cells , in
which the presentation of antigenic EBNAI determnants is prevented due to a domain in
EBNAI that inhibits proteosomal processing, a key step in the endogenous MHC class I
processing pathway. This study highlights the importance of the method used to stimulate
virus-specific CD8+ T cell responses , and demonstrate the potential of using multiple
approaches to identify novel responses. We did not perform these analyses due to the limited
availability of PBMC from these donors , and further studies will be required to determne
whether the two epitopes described constitute dominant CD8+ T cell epitopes on the HTNV N
protein or whether the method of stimulation used resulted in preferential expansion of a
small subset of virus-specific T cells.
2. CD8+ CTL responses following HFS caused by PUUV infection
Our initial studies focused on human CTL responses in individuals who were infected
with a laboratory strain of HTNV and who had no clinical disease as a result of the infection.
However, many hantavirus infections result in the development of moderate or severe disease
with ample evidence of T cell activation. Analysis of CTL responses after natural infections
is important in order to appreciate the magnitude and diversity of CTL responses that are
elicited by these viruses during disease. In order to address this issue, we analyzed virus-
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specific memory CTL responses in a group of Finnish individuals who had HFRS caused by
PUU infection 6-15 years prior to this study.
Following in vitro stimulation of PBMC with infectious PUU , we detected CTL
activity against one or more PUU protein in 7/11 donors. The PUU Nand G 1 proteins
were recognized by most of the donors (6/7 and 5/7 , respectively), while the G2 protein was
recognized in only 2/7 donors (Table V- I). Greater than one HTNV protein was recognized
by bulk culture T cells in 4/7 responding donors. These results demonstrate that multi-
specific CTL responses can be generated following natural infections with PUU. This is in
contrast to our earlier observation from HTNV -immune donors , in which individual bulk
cultures contained detectable CTL activity against only a single HTNV protein. These
experiments were performed using infectious virus to stimulate the PBMC, which may have
led to more efficient presentation of viral peptides on class I MHC molecules and more
effcient CD8+ T cell activation as discussed.
Six CD8+ CTL epitopes on the PUU N protein were identified from two donors in
this study (Table V -2 & Table IV -2). These epitopes were clustered in the center of the N
protein , between amino acids 173 and 251 , with many of the epitopes overlapping one
another. This clustering of CTL epitopes suggests that this may be a highly immunogenic
region of the PUU N protein. It is unclear why so many CD8+ T cell epitopes are clustered
at the center of the PUUV N protein. It is possible that this region of the protein is rendered
paricularly accessible to the proteosomal processing machinery, or that this region contains
sequences that are preferred for binding to and/or cleavage by the proteosomal subunits.
The isolation of CD8+ CTL lines specific for multiple epitopes on the PUU N
protein ilustrated that the virus-specific CTL response was simultaneously targeted against at
least four epitopes in both individuals (Table IV-2). These data demonstrate that there are
multiple human CD8+ CTL epitopes on the N protein ofPUU , and that the CD8+ CTL
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response in a single individual may be targeted against many epitopes simultaneously. These
data also suggest that no one CTL epitope on the PUU N protein is immunodominant to the
exclusion of other epitopes. Again, this observation is distinct from our limited findings from
HTNV -immune individuals in which we detected CTL specific for only 2 epitopes on the
HTNV N protein in two different donors. As mentioned, infection in the HTNV -immune
individuals was sub-clinical. Although levels of viremia were not measured in any of the
individuals studied, it is possible that the virus was controlled more efficiently in these
individuals compared to those who experienced disease. Rapid elimination of virus may have
limited the stimulation of virus-specific cytolytic T lymphocytes and lead to a more restricted
CTL response. Studies of memory CTL responses in HTNV -immune individuals who had
HFS following natural infections would be required to determne whether the CTL response
to the HTNV N protein is broader than during sub-clinical infection. Conversely, analysis of
memory CD8+ CTL responses following sub-clinical infections with PUUV might reveal a
more limited virus-specific CTL repertoire than seen after clinical infection.
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Table V-I: Summary of bulk culture responses in PBMC from PUUV-immune
individuals
PUU proteins recognized Specificity of CTL
Donor by bulk culture CTL clones isolated (# of clones)
N (42), Gl (1)
N (19), G2 (1)
, Gl , G2 G2 (1)
, Gl , G2
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Table V-2: Summary of CD8+ CTL epitopes identifed on HTNV, PUU and SNV.
Virus CTL Epitope Restricting HLA Amino Acid Sequence
HTNV N 12-20 * B51 NAHEGQL VI
HTNV 421 429 ISNQEPLKL
RPKHYVSMPUUV N 173-81 * B7,
PUVU N204- GLFPTQIQV
PUUV 212 VRNIMSPVM
PUU 43-51 * ECPFIKPEV
PUU N 164-78 * A28 TSFEDINGIRRPKH
PUU N236- IRFMKECPFIE
PUU M731-39 (G2)* A24 HWMDATFNL
SNV B35. LPIIKAL YN 13-
SNV N 234- Cw7 ERIDDFLAA
SNV M664-673 (G2) B35. T AHGVGIIPM
SNV M746-755 (G2) B35. YPWQT AKCFF
*Idetltified in this thesis
(52)
unpublished data
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3. HLA restriction of hantavirus-specific CTL
Genetic factors appear to play an important role in the pathology of hantavirus disease.
As discussed , the HLA haplotype B8 , DR3 was shown to be associated with more severe
HFRS caused by PUUV infection. The PUUV N-specific CD8+ CTL lines that we isolated
from two immune individuals were restricted by a varety of HLA alleles , including A2 , A28
B7 or B8 , indicating that many different HLA alleles are capable of presenting antigenic
peptides from the PUUV N protein. The identification of CTL epitopes on the PUUV N
protein wil be of great value for future studies of acute T cell responses during HFS. This
information wil allow the generation of reagents , such as HLNpeptide tetramers, that can be
used to track the virus-specific CD8+ T cell response during the acute phase of disease. These
studies wil provide insight into the kinetics and magnitude of CD8+ T cell responses during
acute HFS.
We were particularly interested in the CD8+ T cell epitopes that were restricted by
HLA B8 , since this HLA allele is associated with severe disease, and is thus of interest for
studies of acute HFS caused by PUUV. Two HLA B8-restricted epitopes were identified:
N17-81 and 243 51, and memory CD8+ T cells specific for these epitopes could be detected in
the PBMC from 2/12 and 8/12 immune individuals, respectively (Table IV-3). The average
frequencies of memory CD8+ T cells specific for the N17-81 epitope (52-304110 PBMC) were
slightly higher than those specific for the N243 51epitope (13-188/10 PBMC), but these cells
were detectable in only 17% (2/12) of the immune donors tested. In contrast
, memory CD8+
T cells specific for the N243 51 epitope were detectable in the majority (67%) of immune
donors tested, making this epitope an attractive candidate for analysis of acute T cell
responses during HFS. Memory CD8+ CTL specific for the HLA A2 epitope (N204 12) were
detectable in 100% (3/3) of immune donors analyzed. HLA A2 is a common allele in
Scandinavian populations , being present in approximately 40% of the population (198). The
108
high frequency of this HLA allele in Scandinavian populations , combined with the likelihood
that many infected individuals will possess CD8+ T cells specific for this epitope , makes it
another attractive candidate for studies of acute T cell responses. Analysis of this epitope wil
also provide an essential comparison for the quantitation of HLA B8-restricted T cells during
these studies.
Interestingly, none of the donors had detectable numbers of memory CD8+ T cells
specific for the A28-restricted epitope N164 78, or for the A24-restricted epitope on the G2
protein (M731-39), including the donors from whose PBMC the specific CTL lines were
isolated (Table IV-3). This suggests that these epitopes may be subdominant compared to the
A2- and B8-restricted epitopes.
SNV -specific CTL lines that recognized determnants on the SNV Nand G2 proteins
were shown to be predominantly B35-restricted (Table V -2) (115) (unpublished
observations). This is interesting since the HLA allele B35 has been shown to be associated
with severe BPS caused by SNV , and it suggests that B35-restricted CTL responses may be
dominant in these donors during acute BPS.
4. Magnitude and heterogeneity of memory CD8+ CTL in PUU -immune individuals
ELISPOT data presented in Chapter IV demonstrates that CTL specific for the PUU
N protein are abundant in the memory T cell pool of these donors , especially when one
considers the duration of time since exposure to the virus (6- 15 years) and the unlikelihood of
re-infection. CTL specific for N204 12 were found at precursor frequencies ranging from 35-
217/10 PBMC , and were especially abundant in donor 13. CTL specific for N173-81 were
detected at precursor frequencies reaching 300/10 PBMC in donor 1 (Figure IV-5, Table V-
3). Finally, CTLs specific for N243 51 were detected at frequencies ranging from 36-188/10
PBMC , and were most abundant in donors 11 and 13 (Figure IV- , Table V-3).
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Table V-3: Fre uencies ofPUUV N-s ecific memor CD8+ T cells in immune donors
Years since . fre . IFN- + T cells/l06 PBMC Total freq./
Donor acute infect. N 173-82(B7 ,8) N204- 12 (A2) N243-51 (B8) 106 PBMC
304. 87. 444.
ND* 49. 15. 65.
52. 61.4 113.
15.4 15.
36. 36.
13. 13.
188 188
200. 92.4 292.
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These frequencies of PUUV -specific memory CTL are considerably higher than many
frequencies of CTL specific for commonly recognized epitopes on influenza A virus as
measured by IN-y ELISPOT assays (187 , 190). In one study, the highest precursor
frequencies of memory CTL specific for the flu epitopes M158-66 (A2-restricted) and NP38o
(B8-restricted) ranged from 1/3 500- 1/111 000 (9-286/10 PBMC) and 1/15,000- 1167 000 (15-
67/10 PBMC), respectively (187). Like PUU , influenza virus causes an acute infection that
is effectively cleared by the immune system. One major difference between these two viruses
is that influenza virus can periodically boost virus-specific CTL responses by re-infecting
individuals with existing influenza virus-specific T cell memory. This does not appear to
happen in the hantavirus system, in which secondary infections have never been reported.
High levels of PUU -specific antibodies circulate following resolution of infection and these
antibodies can be detected for many years (80, 83). High antibody titers , in combination with
the relatively low mutation rate of the PUUV envelope glycoproteins , probably prevent the
virus from establishing a second infection in an immune individual. Considering the
unlikelihood that the PUU -specific CTL response in these donors had been boosted since
the primary infection , the frequencies of memory CTL observed in these donors were very
high.
Measles virus infection provides an apt comparson to hantavirus infection , since
measles virus immunity also appears to be lifelong. Frequency analysis of measles virus-
specific CTL in healthy adult donors who had childhood infections with measles reported that
100-960 cells per 10 PBMC were virus-specific (199). This group used measles-infected
BLCLs , rather than defined peptide epitopes , as stimulator cells in IF-y ELISPOT assays.
These numbers therefore reflect the total of all measles virus-specific T cells capable of
producing IFN-y in these donors. The total frequency of the PUU -specific T cells analyzed
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in the present study was between 15 and 431110 PBMC (Table V-3). Since we measured the
responses to only 4 CD8+ CTL epitopes , restricted by only 4 possible HLA alleles (A2, A28
B8), we are likely to be underestimating the total PUU -specific T cells responses
possible in the context of a given individual's HLA alleles. In addition , studies in which
virus-specific T cell frequencies were measured by varous techniques demonstrate that the
ELlS POT assay may be up to lO-fold less sensitive than intracellular IFN-y staining and
tetramer staining (200, 201). Thus , our use of the IF-y ELISPOT assay may also result in an
underestimation of the frequency of PUU N-specific CD8+ T cells. The frequencies 
virus-specific CTL responses measured in the present study are also comparable to the
frequencies of many virus-specific CTL in adult donors with chronic virus infections such as
EBV and HIV (201-204). In these systems , CTL precursor frequencies are often very high
probably due to periodic reactivation as a result of the persisting virus infection.
It is likely that the memory CD8+ T cells that are abundant in the memory T cell pool
of these individuals were present during the acute infection. Several studies have shown that
CTL that are present at high frequency during acute infection are also detectable at lower
levels in the memory repertoire, and that hierarchies of epitope recognition seen during acute
infection are largely maintained in memory (205 , 206). Studies cared out during acute
PUU infections wil be required to assess the relative levels of epitope-specific CTL present
during the acute response and determne whether they mirror the hierarchies of epitope-
specific responses in the memory population. We predict that the PUU epitopes defined in
this study wil be detectable at high levels in individuals with acute HFS.
This study provides evidence that PUU -specific memory CTL are not only abundant
in the memory T cell pool , but are also phenotypically heterogeneous. TCR VB analysis of 9
CTL lines specific for PUU N204 12 revealed that at least 5 different VB chains are
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represented in this CTL population (Table IV -6). Several recent studies have examined the
TCR diversity of clones specific for a single , often immunodominant, CTL. The results of
these studies have been quite variable. In some systems , epitope specific CTL displayed
restricted TCR repertoires in which one or a few clones dominated and a bias in VB chain
usage was seen (207-209). Other studies demonstrated extremely diverse TCR repertoires
within populations of CTL with the same specificity (210 , 211). The majority of these studies
have been carred out in viral systems in which the virus establishes a persistent infection
such as HIV , HTL V and EBV (20S , 209). Fewer studies have involved acute viral infections
in which the virus is successfully cleared by the immune system; the most detailed of these
are studies of influenza virus. The TCR diversity seen here is in contrast to the observed bias
for VB17 expression in CTL specific for the influenza M157-68 epitope (207 , 212). The
implications of this heterogeneity are unknown, but the existence of many T cell clones with
the same specificity may contribute to a higher level of T cell expansion during the acute
infection.
Although this was not specifically addressed in this study, the TCR diversity of the
CTL specific for N 04- 12 may result from the immunodominant nature of this epitope. A study
of CTL responses to L. monocytogenes in mice demonstrated that CTL lines specific for
dominant H- -restricted epitopes express diverse TCR VB chains , while CTL specific for
subdominant H- -restricted epitopes express a more restricted range of VB chains (213). In
that study, spleen cells from L. monocytogenes- immunized mice were stimulated in vitro with
dominant or subdominant peptides at optimal concentrations. Following peptide-specific
expansion , ::90% of the T cells in culture were peptide specific as determned by H2-
tetramer staining. Remarkably, when these CTL lines were stained with mAbs specific for 
different VB TCR chains , the cell lines specific for the immunodominant epitopes LLO 91-
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& p60 217-225 showed an extremely diverse TCR-VB repertoire. In contrast, the cell lines
specific for the subdominant epitopes p60 449-457 and mpl 84-92 had very restricted TCR-
VB usage , with only one TCR VB chain (VBI4) being expressed by the CTL line specific for
mpl 84-92.
The different peptide concentrations required by these CTL for target cell recognition
suggests that these TCR also have a wide range of binding affinities for the peptidelHA
complex (Figure IV -3A). This observation emphasizes the diversity of the CTL population
that recognizes the N204 12 epitope. Distinct patterns of cross-reactivity among the CTL lines
specific for several other PUU epitopes also suggest that these populations are polyclonal
(Table IV -4).
5. Imunodominance of hantavirus N protein as a CTL target
The majority of the HTNV - and PUU -immune individuals with detectable
hantavirus-specific CTL in bulk culture responded to the N protein. Two of three of the
HTNV -immune donors had detectable CTL specific for the HTNV N protein in bulk culture
and all of the virus-specific CTL lines isolated from these donors were HTNV N-specific. In
addition , bulk cultures from 6 of the 7 PUU-immune subjects contained PUU N-specific
CTL, and the vast majority of CTL lines isolated from two donors were N-specific (61163).
Further, we demonstrated that memory CD8+ T cells specific for one or more epitopes on the
PUU N protein were detectable in 8 PUU immune donors , even more than a decade after
the acute infection. In contrast, memory CD8+ T cells specific for an epitope on the PUU
G2 protein (M73-39) were not detectable in any of the HLA A24+ donors tested.
The relative abundance of CTL lines specific for N protein compared to those specific
for the Gland G2 glycoproteins , the fact that the majority of hantavirus-immune donors have
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detectable N-specific CTL responses in bulk culture , and the high frequency of PUUV N-
specific memory CTL in immune donors , suggest that the N protein may be the dominant
target of the human CTL response during hantavirus infections. Many factors could
contribute to the dominance of N-specific CD8+ T cell responses. Properties of the PUU N
protein itself may influence the generation of antigenic peptides from the protein , and
contribute to immunodominance. For example , the rate and temporal sequence of translation
of the viral gene products is proportional to the rate of peptide generation, and this could
influence the rate of processing and presentation of viral peptides (214). The hantavirus N
protein is expressed early in infected cells , and may represent the most abundant viral gene
product. In SNV infected Vero E6 cells , Hutchinson and colleagues demonstrated that the N
mRNA appeared earlier and accumulated to higher levels than the glycoprotein or polymerase
mRNA species (215). Another study demonstrated that the kinetics of the expression and
accumulation of the PUUV N protein precisely mirrored the kinetics of SNV N mRNA
expression , with protein detectable by 4 hours post-infection and significant accumulation
evident 48 hours post-infection (106). However, in that study, the expression of the N protein
was not compared to the other PUU gene products. The studies described here suggest that
the N protein is a dominant target of the human anti-viral T cell response , although the
mechanisms that may contribute to this dominance have not been investigated.
We were able to isolate three PUU glycoproteins-specific CTL lines: 1 Gl-specific
CTL lines from donor 1 , IG2-specific CTL line from donor 2 , and 1 G2-specific CTL line
from donor 3. This demonstrates that there are antigenic CTL determnants on these proteins.
The paucity of CTL lines specific for Gland G2 may reflect the presence of fewer antigenic
epitopes on the envelope glycoproteins relative to the N protein , or simply that glycoprotein-
specific precursor CTL are less abundant than those specific for the N protein. Alternatively,
since the expression of the glycoproteins in the recombinant vaccinia viruses used to infect
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target cells for sl Cr-release assays was very low relative to that of the N protein (M.
Terajima, manuscript in preparation), there may be insufficient numbers of peptide-MHC
complexes on the surface of the target cells to allow sensitization of glycoproteins-specific
CTL clones. Other studies have demonstrated that the abundance of peptide-MHC complexes
on the surface of a cell can vary considerably, depending on the system used to express the
protein from which the antigenic peptide is derived. Using BPLC extraction of peptides
bound to class I MHC molecules in mice, Rammensee et al. demonstrated that a Db-restricted
influenza nucleoprotein (NP) epitope was present at approximately 300 copies per influenza
virus infected cell (216). Using the same method , a later study showed that only 30
copies/cell of the same epitope were present when a recombinant vaccinia virus expressing
the NP protein was used to infect the cells (217). It is thus possible that our inabilty to isolate
more PUUV glycoprotein-specific CTL lines simply reflects the ineffciency of the expression
of these proteins in vaccinia virus vectors , although this was not specifically addressed.
Previous studies of virus-specific CTL responses during acute BPS caused by SNV
infection resulted in the identification of 2 CD8+ CTL epitopes on the SNV N protein, and 2
CD8+ epitopes on the SNV G2 protein (Table V -2). This demonstrates the existence of CD8+
T cell epitopes on multiple viral proteins, but does not suggest that one protein elicits a
dominant response. Studies performed during acute BPS comparng the relative magnititudes
of the CD8+ T cell response to the epitopes on Nand G2 may reveal whether or not the N
protein is also the dominant target of SNV -specific CTL.
B. CROSS-REACTIVITY OF HANTA VIRUS-SPECIFIC CTL LINES
There are at least 20 distinct hantaviruses, approximately half of which are known to
cause human disease. We are interested in whether protective immunity against one
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hantavirus might confer immunity against other hantaviruses. There have been no reported
cases of hantavirus re-infection in individuals with existing immunity to a particular
hantavirus , and it is thus thought that recovery from hantaviral infection results in life-long
immunity. However, it is not known whether immunity to one virus may confer some
protection against other strains of hantavirus or, alternatively, whether immunity against one
hantavirus may predispose an individual to immunopathology in the event of a second
infection. Although many different hantaviruses are thought to be very geographically
isolated from one another, recent studies have shown that there are regions in which more
than one distinct hantavirus co-circulate (188). The co-circulation of different hantaviruses
as well as the possibility of exposure to different viruses during travel , highlights the potential
importance of cross-reactive immunity.
1. Cross-reactivity of CTL lines isolated from HTNV -immune donors
Cross-reactivity studies conduct d with the CTL lines isolated from the HTNV-
immune donors revealed that some CTL were cross-reactive with many different
hantaviruses , while others were highly specific. Most of the observed cross-reactivity (or lack
thereof) could be attributed to sequence homology among the different viruses at the given
epitope. However, among CTL lines that recognized the same epitope, complex patterns of
cross-reactivity were noted.
The three CTL lines specific for amino acids 12-20 (NAHEGQL VI) were all restricted
by HLA B51 and were either HTNV -specific or recognized only the very similar SEOV
epitope (SAHEGQL VI) (Figure III-4 , III-6A). The consensus motif for peptides binding to
HLA B51 consists of anchor residues at positions 2 (A G) and 9 (L V,I) (189). This HTNV
N peptide fits the consensus B51 peptide binding motif with an alanine (A) at position 2 and
isoleucine (I) at position 9. It is not surprising that the clones specific for this epitope failed to
117
recognize the corresponding region of other hantaviruses since this region of the nucleocapsid
protein is quite variable among different viruses , with many of the amino acid differences
occurrng at the anchor positions for HLA binding (Fig. III-6A). The corresponding epitope
from DOBV differs from the HTNV epitope by only one amino acid. However, the amino
acid change in the DOBV epitope is located at the anchor position 2 (A13-7N). 
hypothesized that this substitution may result in an inability of the peptide to bind the HLA
B51 molecule and this could explain the lack of recognition by the CTL lines. It is interesting
to note that the HLA B51 is very common among populations in Asia, where HTNV is
endemic , being present in a higher portion of the population (8- 12%) than most other HLA
alleles (198).
The CTL lines that recognize the C-termnal nine amno acids of the HTNV N protein
(421-429: ISNQEPLKL) are restricted by HLA Al and are cross-reactive against several
different hantaviral sequences (Figure V - , III-6B). Interestingly, this peptide does not fit the
consensus HLA Al binding motif in which an acidic residue (D , E) is preferred at position
three and a tyrosine (Y) is highly preferred at the anchor position 9 (189 , 218). The restricting
allele for this CTL epitope , HLA- , is common in North American Caucasian populations
(17- 19%) but is relatively rare among Asian populations (0. 5%) (198), so the importance of
this epitope among individuals in areas where HTNV is endemic remains to be determned.
Studies of CTL responses in HFS patients from Asian countries wil be required to
determne whether this epitope is a target of CTL during natural infections.
The N421 429 epitope is identical among varous hantaviruses including SNV, ANDV
NYV , and DOBV and differs from the PUU , PHV and BA YV epitope by a single
conservative change at position 9 (L429-7I). The corresponding epitope from SEOV also
differs by one amino acid with a substitution at position 7 (L427-7M) (Figure III-6B). The
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sequence conservation at this epitope and the recognition of target cells expressing SNV N
protein by CTL, suggest that infection with HTNV induces some cross-reactive T cell
responses. This cross-reactive epitope is particularly interesting in that it is identical among
not only closely related viruses that cause HFS (e.g. HTNV and DOBV) but also among
viruses that are more distantly related and cause distinct syndromes (e.g. HTNV and SNV).
The data presented here demonstrate that infection with HTNV results in the
development of both HTNV -specific and hantavirus cross-reactive CD8+ T cell responses,
with distinct patterns of cross-reactivity among CTL lines that recognize the same epitope
(Table V-4). This suggests that immune individuals may be protected to some extent from
secondary infections with other hantaviruses. Additionally, individuals vaccinated with a
vaccinia virus encoding the HTNV M segment had detectable proliferative responses to both
HTNV and SNV , indicating that a cross-reactive CD4+ T cell response was generated in these
indi viduals (175). The SNV -specific CTL lines established in our laboratory also included
both SNV-specific and cross-reactive lines (115).
Cross-reactivity of virus-specific CTL is a common phenomenon that has been
described in many viral systems. Individuals who received a live , attenuated dengue virus
immunization develop both serotype-specific and serotype cross-reactive T cell responses
(117, 219, 220). Similarly, studies of human CTL responses to influenza viruses
demonstrated that CTL specific for epitopes on conserved, internal proteins can recognize
other strains of influenza virus that infect humans as well as those that target avian and swine
species (190, 221). The abilty of human memory CTL responses to recognize determnants
from avian influenza viruses was speculated to account for the limited spread of the "Hong
Kong" influenza virus from chickens to humans in 1997.
Murine studies have demonstrated that immunization with one type of hantavirus
elicits protective CTL responses that are cross-reactive with other hantaviruses (93 , 222). 
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those studies , spleen cells from PUUV or PHV -immunized mice were shown to have cytolytic
activity against HTNV -infected target cells in Cr-release assays , following short term 
vitro stimulation with HTNV -infected macrophages (222). Additionally, the transfer of
PUUV -immune splenocytes in nude mice was shown to significantly reduce titers of HTNV
in the lung and spleen when transferred 1 day prior to challenge with HTNV. This
demonstrates that hantavirus-specific T cells were able to confer cross-reactive protection
against heterologous viruses in mice. A similar cross-reactive response to SEOV was induced
following immunization of mice with HTNV (93).
This is the first demonstration that cross-reactive CD8+ CTL responses are also
generated in humans following infection with HTNV. In addition to providing protection
against subsequent infection , it is also possible that activation of cross-reactive memory CD4+
and CD8+ T cells may be deleterious in the event of re-infection , by contributing to excessive
activation of the immune response and resulting immunopathology.
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Table V-4: Cross-reactivity of CD8+ CTL lines isolated from HTNV-immune subjects
Epitope Donor CTL Line HTNV SNV PUU SEOV DOBV ANDV PHV
N12-
10- E2
3A-
N421-429
lA-
3A-
3A-
3A-ClO
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2. Cross-reactivity of CTL lines isolated from PUUV-immune donors
The epitopes identified in this study are clustered near the center of the PUU N
protein in a region that shares relatively little sequence identity among the different
hantaviruses. It was not surprising, therefore , to find that the majority of the CTL lines
isolated in this study failed to recognize target cells expressing the N protein from either
HTNV or SNV (Tables IV-4 & IV-5). However, we did find three CTL lines (l0- , IB-
and 3-B8) that displayed cross-reactive lysis of target cells infected with recombinant vaccinia
viruses expressing either the HTNV or SNV N protein. The epitope recognized by 1O-
(N17-81) is well conserved between PUU , HTNV and SNV (Table IV -5). CTL line 1O-
recognizes the epitope from PUU and HTNV , which differ by only two amino acids.
However, CTL line 3- , which is specific for the same peptide/HA combination , did not
recognize the HTNV N protein. Similarly, CTL line IB-G9 was the only one of seven lines
specific for N236 so that recognized targets expressing both PUUV Nand SNV N (Table IV-4).
In this case , there was little sequence conservation at this epitope among the viruses. Finally,
the CTL line specific for PUU N164-78 (3-BS) cross-reacted with targets expressing the
HTNV , but not the SNV , N protein. The minimal epitope recognized by this cell line remains
to be characterized, but the 15-mer sequence differs between PUUV and HTNV by only 3
amino acids , all of which are conservative substitutions (T --S , I-- V, R--K) that are likely to
preserve the integrity of the antigenic epitope. The corresponding SNV sequence differs from
the PUU sequence by 6 amino acids , all of which constitute conservative substitutions.
In contrast to our earlier data, which suggested that hantavirus infections elicit both
virus-specific and cross-reactive CTL responses , these data suggest that the virus-specific T
cell responses in these individuals were largely PUU-specific (Table V-5). Additional
studies of acute and memory CTL responses in infected or immune individuals are required to
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determne the extent of cross-reactivity of cytotoxic T cells that are generated during
hantavirus infections.
Table V -5: Cross-reactivity of CD8+ CTL lines isolated from PUUV -immune subjects
Epitope HLA # CTL lines # x-reactive # x-reactive
Restriction with HTNV with SNV
N204-
N173-
N173-
N236-
N212-
N164- A28
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C. SUMRY
This thesis provides the first analysis of human memory CD8+ T lymphocyte
responses to the Old World hantaviruses HTNV and PUUV. Overall, the data from these
studies suggest that the N protein is the dominant target of CD8+ T cell responses during
PUUV infection and, although the data are very limited, the N protein may also be
immunodominant during infection with HTNV and other hantaviruses. The PUUV N-specific
CTL response , which is focused on a cluster of epitopes between amino acids 173 and 215,
appears to be broad , heterogeneous and largely PUU -specific. The data also show that
PUU N-specific CTL persists for more than a decade after the acute infection at high
frequencies that are comparable to or exceed those measured for other acute viruses such as
influenza and measles , as well as for chronic viruses such as EBV and HIV.
In summary, the results presented in this thesis examine virus-specific memory T
lymphocyte responses following sub-clinical infections and clinical , naturally-acquired
infections with hantaviruses that cause HFS. The major findings are:
1. CD4+ and CD8+ virus-specific T cell responses can be detected following sub-clinical
laboratory-acquired infections with HTNV, the prototype hantavirus. Two novel CD8+ CTL
epitopes were identified on the HTNV N protein. Sub-clinical infections with HTNV induced
both HTNV-specific and hantavirus-cross-reactive CD8+ T cell responses.
2. CD4+ and CD8+ virus-specific T cell responses can be detected in healthy adults following
resolution of HFS caused by PUUV infections, and the PUUV N protein appears to be the
dominant target of the virus-specific T cell response in these individuals. Infection elicits a
broad response to the PUUV N protein, with CTL specific for multiple epitopes being
detectable in a single indi vidual. Six novel CD8+ CTL epitopes and one novel CD4 + CTL
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epitope were defined on the PUU N protein and the majority of T cell lines specific for these
epitopes were PUUV -specific.
3. CD8+ memory CTL specific for several epitopes on the PUU N protein can persist at
high frequency in the peripheral blood for at least 15 years after resolution of the acute
infection , despite the fact that memory CD8+ T cell responses are unlikely to be boosted
during that time.
A quantitative RT-PCR assay was developed and optimized and may be used to
measure levels of PUUV RNA in acute patient sera. This assay wil provide critical
information regarding the kinetics and magnitude of the virus load during PUU infection.
These studies were initiated as a result of our hypothesis that virus-specific T cells
may be involved in immunopathogenesis during HFS. While the studies described in this
thesis do not elucidate the role that T cells play in the pathogenesis of disease , they provide
the information necessary to address this question. As a direct result of these studies, it wil
be possible to directly examine PUU specific CD8+ T cell responses during acute HFS.
The identification of epitopes on PUU wil allow us to track virus-specific T cell responses
through the acute phase of disease and into convalescence using sensitive techniques such as
peptide/MC tetramer staining and intracellular cytokine staining. These studies wil provide
the first clues regarding the kinetics and magnitude of the CDS+ T cell response during acute
HFS. This quantitative information can be compared to virus load and to clinical parameters
that reflect disease severity, and wil provide insight into the potential role of CD8+ T
lymphocytes in the pathogenesis of HFS. More generally, this system wil provide a well-
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defined human model of virus infection in which to study basic immunological concepts such
as the establishment and maintenance of long-term virus-specific T cell memory.
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APPENDIX I
DESIGN AND OPTIMIZATION OF A QUANTITATIVE RT -PCR ASSAY TO
MEASURE PUUV RNA COpy NUER IN PLASMA OF PATIENTS WITH HFRS
The pathogenesis of HFRS is not well defined, but we and others hypothesize that T
lymphocyte activation and cytokine responses are likely to contribute to disease pathogenesis.
Another parameter that may impact the severity of ilness resulting from hantavirus infection
is the virus burden. Higher virus titers may result in a more robust immune response and thus
contribute to immunopathology. To better understand the role of the virus load in the
pathogenesis of disease , we developed a quantitative RT-PCR assay to measure PUU 
segment RNA copy number in the plasma of patients with HFS.
Our laboratory had previously designed a similar RT-PCR assay to measure SNV S
segment RNA copy number in patients with BPS (10S). In that study, RNA copy number was
measured in 26 patients with BPS , at one or more time points during the acute ilness. The
results showed that viral RNA copy number correlated with several parameters of disease
severity. There was a positive correlation between vRNA copy number and peak hematocrit
levels , and an inverse correlation with nadir platelet count , suggesting that higher viral burden
is associated with more severe ilness. In addition , the mean vRNA copy number was 110glO
higher in fatal cases than in survivors , again suggesting that higher virus titers are correlated
with greater disease severity. The previous study also showed that, in S patients who
survived, vRNA copy numbers decreased to undetectable levels in samples taken after fever
resolution. We predict that vRNA copy number may also correlate with severity of HFS
following PUU infection.
A previous study demonstrated that PUU S segment RNA could be amplified by
RT-PCR from the PBMC and urine of patients with HFS (158). In that study, 3 of 15
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PBMC and 4 of 6 urine specimens were positive for PUU S segment vRNA. Interestingly,
5 of 6 PCR-positive patients (83%) expressed the HLA haplotype B8 , DR3 , which was
previously shown to be correlated to more severe ilness following PUU infection. In
contrast , only 1 of 11 (9%) PCR-negative patients possessed this haplotype. The abilty to
detect vRNA by PCR also correlated with several clinical parameters that reflect disease
severity including thrombocytopenia, requirement for dialysis and length of hospital stay,
although these correlations were not statistically significant. These data suggest that virus
load in PUU infection may also be associated with more severe disease, as we have seen in
BPS caused by SNV.
A. Design of a competitor plasmid for PUUV-speciflc RT-PCR.
To create a competitor plasmid from which to generate negative stranded RNA for
PUU-specific RT-PCR, we used a plasmid generated previously in our lab (pFIR2+118)
(108), which contains the SNV S segment cDNA (nt 42-309) and an additional 118-base pair
segment (see Materials and Methods). To use this competitor plasmid for a PUU-specific
PCR , we engineered PUU -specific primer binding sites at the ends of the SNV S segment
by PCR amplification of the SNV S segment. The primers used to amplify the segment were
PUU/SNV "hybrid" primers , and PCR amplification resulted in a product identical to the
staring product with PUU -specific primer binding sites at either end of the SNV S segment
(Figure V- I). Although the RNA that results from this competitor plasmid wil consist mostly
of SNV S segment sequence , we hypothesized that the PCR amplification of this RNA would
be comparable to the amplification of PUUV S segment RNA , since the nucleotide sequence
of the PUU and SNV S segments are 70% identical in this region and the sequences do not
contain highly G/C rich regions. Positive control RNA was generated from a plasmid
, pSP72-
1 tr, that contains a portion of the PUU K27 S segment.
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SNV -specific
PUUV-specifi
HaeII di""tion to cut olasmid voctm
PUUSNV primer
PUUV-specific 
primer binding sites
PCR Amolification
UUSNVR primer
Figure A-I: Schematic showing the construction of the competitor plasmid for PUU virus-
specific RT-PCR
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B. Sensitivity of RT - PCR for amplification of positive control and competitor RNA.
To assess the sensitivity of our RT-PCR system, we made seriallO-fold dilutions of
the competitor and positive control RNA and added a known quantity of RNA (S segment
copy number) to each PCR reaction tube. Figure V-2A shows the sensitivity of the RT-PCR
for the competitor RNA. A band is visible in the reaction containing lX10 RNA copies, and
a faint band is visible in the reaction containing lX10 RNA copies. This indicates that at
least 100- 1000 competitor RNA copies are required for detection in this assay. The
sensitivity of the RT-PCR assay for the positive control RNA was comparable to the
sensitivity for the competitor RNA , and required approximately lX10 copies for detection
(Figure V -2B).
To quantitate the viral RNA in patient plasma, the RT-PCR reaction is performed with
both the competitor RNA (known concentration) and the viral RNA (unknown concentration)
in the same tube. To insure that the RT-PCR assay amplified both the competitor RNA and
viral RNA appropriately in the same tube, we placed a constant concentration of positive
control RNA in each tube and added seriallO-fold dilutions of competitor RNA to the
successive tubes. The band intensities of the resulting PCR products should be equivalent in
the tubes containing equivalent numbers of copies of positive control and competitor RNA
species. Figure V-2C shows that the band intensities of the competitor and control RNA
products are indeed comparable in the reactions that contained equal numbers of copies of the
two RNA species. We did not see any non-specific PCR products in any of these
experiments.
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Competitor: RNA copies/rxn:
Positive Control: RNA copies/rxn: 
Competitor: RNA copies/rxn:
Pos. control: RNA copies/rxn:
Figure A-2: Sensitivity of quantitative RT-PCR assay for detection of PUU S segment
RNA. 1 j.l of competitor RNA (FIR2+11S-S) and/or positive control RNA (pSP72- ltr) was
amplified in each reaction tube. PCR products were separated on a 2% agarose gel and
visualized by ethidium bromide staining.
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Since the prior optimization experiments utilized only in vitro transcribed RNA , it was
necessary to show that viral RNA was also amplified efficiently under these conditions. We
amplified vRNA isolated from supernatants of Vero E6 cells infected with PUUV (strain
K27) after the first or second passage. A constant amount of viral RNA (1 J.l) and the
indicated amount of competitor RNA was added to each tube. Figure V-3 demonstrates that
the PUUV vRNA was amplified efficiently, and that the supernatant from the first virus
passage contained approximately 10 RNA copies/J.l. The supernatant from the second RNA
passage contained between 10 and 10 RNA copies/ml. These data demonstrated that PUUV
RNA could be amplified efficiently using this newly developed RT-PCR assay.
Competitor: RNA copies/rxn:
Passaged virus (1 IlVrxn): Passage 1 Passage 2
Figure A-3: Amplification ofPUU (K27) virus grown in Vero E6 cells. Supernatants
were collected from PUU after passage 1 or 2 and stored at - C until use. vRNA was
prepared from 140 III of infected cell supernatant using the QIAamp viral RNA isolation kit
(Qiagen , Valencia , CA) and 1 J.I of vRNA was included in each reaction tube. PCR products
were separated on a 2% agarose gel and visualized by ethidium bromide staining.
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c. Specificity of RT -PCR.
To show that the RT-PCR assay was specific for PUUV RNA and would not amplify
viral RNA from other hantaviruses , we isolated viral RNA from several different strains of
hantavirus including PUUV, SNV , HTNV , and SEOV. One f.1 of vRNA was added to each
tube and RT-PCR was performed in the absence of competitor RNA. Figure V-4 shows that a
PCR product was visible only in the reaction containing the PUUV RNA and the positive
control RNA, and no bands were visible in the reactions containing RNA isolated from other
hantaviruses. These data indicated that the RT-PCR was specific for PUUV RNA.
Figure A-4: Specificity of PUUV RT-PCR assay. Viral RNA was isolated from 140 f.1 of
supernatant from passaged viruses including PUUV, SNV, HTNV and SEOV. 1 f.1 of vRNA
or positive control RNA (pSP72- ltr) was amplified in each reaction tube. PCR products were
separated on a 2% agarose gel and visualized by ethidium bromide staining.
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D. Attempt to amplify PUUV-specific RNA from patient plasma
Initial attempts were made to amplify PUUV -specific RNA from plasma samples
drawn from a small group (n=9) of Finnish patients with acute HFS caused by PUUV
infection. Whole blood was drawn by venipuncture and PBMC were separated in Vacutainer
CPT tubes (Becton Dickinson , Rutherford, NJ). Plasma was removed from the tubes and
frozen at - C until use. Viral RNA was isolated and 1 J.d of vRNA was added to each PCR
tube. We wanted to first determne if any of the plasma samples contained viral RNA , so we
did not include competitor RNA in the initial experiment. None of the plasma samples
contained detectable levels of PUU RNA (data not shown). It is possible that the virus had
already been cleared in these patients or that the level of viral RNA was below the limit of
detection of our assay.
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